

Subject Index

A

abatacept

- rheumatoid arthritis - Orencia (New drug) 30(6) 163-7

abnormal laboratory results - see also diagnostic tests

- abnormal haematology results in children 27(3) 64-6
- abnormalities in pregnancy 29(2) 48-52
 - letter 29(4) 91-3
- adrenocortical function in adults 30(6) 147-9
- antibodies to cyclic citrullinated peptides in rheumatoid arthritis 29(6) 162-4
- biochemical tests in pregnancy 28(4) 98-101
 - letters 29(1) 3-5; 28(6) 136-9
- cell markers 30(5) 128-9
- C-reactive protein 30(3) 74-6
- magnesium 30(4) 102-5
 - letter 30(6) 140-41
- paediatric biochemical tests 28(5) 126-9
- sexually transmitted infections 30(1) 8-13

abnormalities, congenital - see birth defects

Aboriginal people

- Aboriginal primary health care (book review) 27(1) 9
- CARPA Standard Treatment Manual (book review) 27(1) 8
- drug therapy
 - letter 27(3) 55-7
- medication management 28(5) 123-5
 - letters 29(6) 149-50; 29(3) 59-62

ACE inhibitors

- vs diuretics in hypertension 27(4) 98-101

acetylcholinesterase inhibitors

- donepezil in Alzheimer's disease (editorial) 28(6) 134-5
 - letter 29(3) 59-62

Aclor

- see cefaclor 27(1) 21-3

acne

- isotretinoin in cystic acne 28(3) 59-61
- polycystic ovary syndrome 27(5) 129-31
- tazarotene - Zorac (New drug) 29(3) 84-7

ACTH

- see adrenocorticotrophic hormone 30(6) 147-9

acute-phase reaction

- C-reactive protein 30(3) 74-6

adalimumab

- Humira - rheumatoid arthritis (New drug) 27(4) 101-5
- rheumatoid arthritis 27(2) 43-6
- tumour necrosis factor blockers in rheumatology 29(3) 67-70

Addison's disease

- abnormal laboratory results 30(6) 147-9

adefovir dipivoxil

- Hepsera - hepatitis B (New drug) 27(6) 159-65

adrenal gland cancer

- iobenguane - MIBGen - tumour localisation (New drug) 27(5) 131-3

adrenaline

- management of anaphylaxis - wallchart 30(5) 115
- repeat prescriptions of EpiPen auto-injectors (PBAC question) 28(4) 90
- shelf-life of EpiPen (PBAC question) 29(2) 52-3

adrenocorticotrophic hormone

- abnormal laboratory results 30(6) 147-9

adverse effects - see also birth defects; drug interactions

- Adverse Drug Reactions Advisory Committee 28(6) 140-2
- Adverse Medicine Events Line 28(4) 102; 27(2) 38
- adverse reaction reporting 28(6) 140-2
 - dental notes 28(6) 142
- alcohol and paracetamol hepatotoxicity 27(1) 14-5
- amiodarone in arrhythmia 28(6) 150-4
- antidepressants in pregnancy and breastfeeding 30(5) 125-7
- antipsychotic drugs
 - atypical vs typical 27(6) 146-9; 27(6) 149-51
 - in pregnancy and breastfeeding 30(6) 162-3
 - and risk of diabetes 27(5) 118-9
- aspirin, alcohol and gastric bleeding 28(1) 18-9
 - letter 28(4) 84-7
- asthma with ibuprofen 27(4) 87
- bisphosphonates and avascular necrosis of the jaw (letter) 27(2) 28-33
- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7
- bowel cleaning preparations 28(1) 16-7
- cabergoline-induced valvulopathy 31(1) 21
- cephalosporins and penicillin allergy 30(1) 25-6
- Chinese medicines
 - letter 27(2) 28-33
- chiral drugs - pharmacology and efficacy 27(2) 47-9
 - letter 27(5) 109-13
- ciprofloxacin and fever (letter) 28(6) 136-9
- cross-reactivity of penicillins and cephalosporins 30(1) 25-6
- digoxin - brands and dosages 29(6) 153
 - letter 30(2) 32-4
- fenofibrate-warfarin interactions 29(6) 166
 - letter 30(2) 32-4
- gingival bleeding 29(6) 154-5
- headache and analgesic overuse 28(6) 143-5
 - letter 29(3) 59-62
- hyponatraemia
 - letters 27(3) 55-7; 27(2) 28-33
 - with omeprazole 28(2) 48-9
- ibuprofen and asthma 27(4) 87
- interstitial nephritis with omeprazole 30(3) 67
- intravenous potassium chloride 28(1) 14-6
 - letters 28(4) 84-7
- isotretinoin in acne 28(3) 59-61
- MedSafety online learning system for medication error prevention (letter) 27(5) 109-13
- metformin in pregnancy and lactation 30(3) 68-9
- metronidazole and breastfeeding (letter) 28(2) 29-33
- muscle symptoms with simvastatin 28(4) 102
- neurocognitive effects of chemotherapy 31(1) 22-4
- neutropenia with quetiapine 31(1) 10-11
- nitrofurantoin risks and benefits (letter) 27(4) 82-3
- NSAIDs and cardiovascular disease in rheumatology (editorial) 29(4) 90-1
- omeprazole and hyponatraemia 28(2) 48-9
- omeprazole and interstitial nephritis 30(3) 67
 - online reporting 28(6) 140-2
 - by consumers 27(2) 38
- osteonecrosis of the jaws with bisphosphonates 30(4) 96-7
- overdoses of over-the-counter Donnalix Infant Drops 29(3) 83
- paracetamol, gastrointestinal bleeding and hypertension (letter) 30(3) 59-63
- pitfalls of prescribing generic drugs (letter) 28(4) 84-7
- polypharmacy (editorial) 31(1) 2-3
- salmeterol (editorial) 29(5) 118-9

- serotonin syndrome
- - over-the-counter dextromethorphan 29(3) 71
- - - letter 29(6) 149-50
- simvastatin and muscle symptoms 28(4) 102
- - letter 28(6) 136-9
- starter packs and drug samples 30(1) 14-16
- sulfonamide allergy and cross-reactivity 31(1) 8-10
- temazepam capsules and injecting drug users 27(3) 58-9
- - letter 27(5) 109-13
- thiazolidinediones 27(3) 67-70; 27(3) 70-4
- - letter 27(6) 138-41
- toxicity with Donnalix Infant Drops 29(3) 83
- tramadol
- - editorial 27(2) 26-7
- - and hyponatraemia 27(4) 97
- - - letter 28(2) 29-33
- vascular effects of COX-2 selective inhibitors 27(6) 142-5
- - letters 28(2) 29-33
- warfarin
- - risks and benefits 27(4) 88-92
- - - cataract surgery (letter) 27(6) 138-41
- xerostomia, drugs and radiotherapy 29(4) 97-8
- - dental notes 29(4) 108
- - letters 30(1) 3-4

Adverse Medicine Events Line

- Adverse Medicine Events Line 27(2) 38
- consumer reporting of adverse drug reactions 28(4) 102
- starter packs and adverse effects 30(1) 14-16

advertising

- AdWatch website review 27(3) 63
- complementary medicines (letter) 30(6) 140-41
- direct-to-consumer advertising 27(1) 4-6
- - in New Zealand 29(2) 30-2
- effectiveness of new drugs (editorial) 27(1) 2-3
- efficacy of Ginkgo biloba in tinnitus (letter) 30(2) 32-4
- gabapentin promotion and off-label prescribing
- - letters 27(4) 82-3
- Medicines Australia - code of conduct breaches 30(6) 153-5; 29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(5) 124-7; 27(3) 60; 27(1) 6-7
- - vardenafil 30(6) 154
- regulatory framework in Australia 27(5) 124-7
- retail pharmacy promotions (letter) 27(2) 28-33

AdWatch

- website review 27(3) 63

agalsidase alfa

- Replagal - Fabry's disease (New drug) 27(5) 131-3

agalsidase beta

- Fabrazyme - Fabry's disease (New drug) 27(5) 131-3

aged

- beta blockers in hypertension 30(1) 5-7
- Pharmaceutical Benefits Scheme restrictions on analgesics (PBAC question) 27(6) 155
- - update 28(1) 13
- polypharmacy (editorial) 31(1) 2-3

AIDS - see HIV/AIDS

alcohol

- aspirin and gastric bleeding 28(1) 18-9
- - letter 28(4) 84-7

alcohol dependence

- paracetamol hepatotoxicity 27(1) 14-5

aldosterone

- abnormal laboratory results 30(6) 147-9

Aldurazyme

- see laronidase 30(3) 79-82

alefacept

- amevice - chronic plaque psoriasis (New drug) 27(4) 101-5

alemtuzumab

- MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71

Alimta

- see pemetrexed disodium 28(1) 19-23

allergy

- monoclonal antibodies 29(5) 130-3
- penicillins and cephalosporins (medicinal mishap) 30(1) 25-6
- sulfonamide allergy and cross-reactivity 31(1) 8-10

alpha fetoprotein

- biochemical tests for abnormalities in pregnancy 29(2) 48-52

alpha-1-antitrypsin deficiency

- chronic obstructive pulmonary disease (letter) 30(6) 140-41

alternative medicines - see complementary medicines

Alvesco

- see ciclesonide 28(4) 104-6

Alzheimer's disease

- donepezil (editorial) 28(6) 134-5
- - letter 29(3) 59-62
- management of behavioural problems 28(3) 67-70
- mental status testing 28(1) 11-3
- patient support organisations 28(3) 72
- risperidone for behavioural disturbances (RADAR comment) 28(3) 71

AME Line

- consumer reporting of adverse drug reactions 27(2) 38

Amevice

- see alefacept 27(4) 101-5

amiodarone

- arrhythmia 28(6) 150-4

amisulpride

- schizophrenia - Solian (New formulation) 27(3) 76-9

amoxicillin

- Maxamox (New formulation) 27(1) 21-3

amphetamines

- adverse effects 29(4) 109-11

anaemia

- blood transfusion guidelines 28(2) 45-7
- epoetin beta - Neorecormon - recombinant erythropoietin (New drug) 29(4) 112-5
- iron sucrose - haemodialysis - Venofer (New drug) 28(2) 49-51
- - letter 28(4) 84-7

anaesthetics

- articaine with adrenaline - Septanest, Deltazine, Bucanest - dental anaesthesia (New drug) 28(1) 19-23
- managing painful paediatric procedures 29(4) 94-6
- - dental notes 29(4) 108
- - letters 29(6) 149-50

anakinra

- Kineret - rheumatoid arthritis (New drug) 27(6) 159-65

analgesia

- lumiracoxib - Prexige (New drug) 29(1) 25-7
- perioperative 27(6) 152-4
- - letter 28(2) 29-33
- Pharmaceutical Benefits Scheme restrictions and the aged (PBAC question) 27(6) 155
- - update 28(1) 13
- pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9

analgesics (see also anti-inflammatory drugs)

- alcohol and paracetamol hepatotoxicity 27(1) 14-5
- headache and analgesic overuse 28(6) 143-5
- - letter 29(3) 59-62
- lumiracoxib - Prexige (New drug) 29(1) 25-7
- pethidine - in pain management
- - in labour pain 27(2) 34-5
- tramadol - Tramal (New drug)
- - adverse effects (editorial) 27(2) 26-7

anaphylaxis

- repeat prescriptions of adrenaline auto-injectors (PBAC question) 28(4) 90
- wallchart Emergency management of anaphylaxis in the community 2007 30(5) 115

anecortave

- Retaane - macular degeneration (New drug) 29(2) 53-5

angina - see also coronary disease

- ivabradine - Corolan (New drug) 30(2) 50-55

angiogenesis inhibitors

- in cancer - clinical applications 29(1) 13-5
- in cancer - pharmacology 29(1) 9-12
- erlotinib - Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5
- renal cell cancer 29(6) 151-3
- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71
- sunitinib - Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71

angiography

- magnetic resonance imaging in neuroradiology 31(1) 18-20

Angiomax

- see bivalirudin 28(3) 75-9

angiotensin converting enzyme inhibitors - see ACE inhibitors**angiotensin receptor antagonists**

- olmesartan medoxomil - Olmetec (New drug) 30(3) 79-82

anti-inflammatory drugs - see also**analgesics**

- COX inhibitors
- - vascular effects of COX-2 selective inhibitors 27(6) 142-5
- - - letters 28(2) 29-33; 28(2) 29-33; 28(2) 29-33
- dental and oral pain, management 30(3) 77-9
- gout, management 27(1) 10-3
- ibuprofen-induced asthma 27(4) 87
- NSAIDs and cardiovascular disease in rheumatology (editorial) 29(4) 90-1

antiarrhythmic drugs - see arrhythmia**antibiotics**

- cephalosporins and penicillin allergy 30(1) 25-6
- cross-reactivity of penicillins and cephalosporins (medicinal mishap) 30(1) 25-6
- dental and oral pain, management 30(3) 77-9
- foot infections in diabetes 30(1) 21-4
- management of animal and human bites 29(1) 6-8
- - letters 29(3) 59-62
- nitrofurantoin risks and benefits (letter) 27(4) 82-3
- resistance
- - community-acquired methicillin-resistant *Staphylococcus aureus* infection 28(6) 155
- - - letter 29(3) 59-62
- - prevention of antibiotic resistance 27(2) 39-42
- - - letter 27(6) 138-41
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5

- sulfonamide allergy and cross-reactivity 31(1) 8-10
- surgical prophylaxis 28(2) 38-40
- - dental notes 28(2) 41
- - letters 28(5) 113-5; 28(3) 55-8
- Therapeutic Guidelines - Antibiotic - book reviews 30(3) 73
- tigecycline - complicated infections - Tygacil (New drug) 29(5) 138-43

antibodies, monoclonal - see monoclonal antibodies**anticancer drugs - see antineoplastics****anticholinergic drugs**

- darifenacin hydrobromide - overactive bladder - Enablex (New drug) 29(5) 138-43
- overactive bladder 29(1) 22-4
- - letter 29(4) 91-3
- overdoses in infantile colic 29(3) 83
- solifenacin succinate - overactive bladder - Vesicare (New drug) 29(5) 138-43
- tolterodine - overactive bladder - Detrusitol (New drug) 28(2) 49-51
- toxicity with Donnalix Infant Drops (medicinal mishap) 29(3) 83

anticoagulants

- bioequivalence of Marevan and Coumadin (letter) 30(2) 32-4
- bivalirudin - percutaneous coronary intervention - Angiomax (New drug) 28(3) 75-9
- gingival bleeding 29(6) 154-5
- human protein C - Ceprotrin - congenital protein C deficiency (New drug) 30(2) 50-55
- warfarin
- - dental extractions (letter) 27(1) 3
- - interactions with fenofibrate 29(6) 166
- - - letter 30(2) 32-4
- - risks and benefits 27(4) 88-92
- - - cataract surgery (letter) 27(6) 138-41

anticonvulsants

- in bipolar disorders 30(3) 70-3
- management of behavioural problems in dementia 28(3) 67-70
- in neuropathic pain 29(3) 72-5
- pregabalin - Lyrica (New drug) 28(3) 75-9
- withdrawal of antiepileptic drugs in seizure-free adults 27(5) 114-7
- withdrawal of drugs from seizure-free children 29(1) 18-21

antidepressant drugs

- depression in medical illness 30(4) 86-8
- drug-induced hyponatraemia
- - letters 27(2) 28-33
- escitalopram oxalate - serotonin reuptake inhibitor - Lexapro (New drug)
- - letter 27(2) 28-33
- management of behavioural problems in dementia 28(3) 67-70
- management of mild depression in general practice 28(1) 8-10

- 'Medicines out of control?' (book review) 27(5) 117
- neuropathic pain 29(3) 72-5
- pregnancy and breastfeeding 30(5) 125-7
- psychotropic drugs for children in general practice 28(5) 116-8
- suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5
- treatment of non-depressive disorders 28(4) 91-3

antiemetics

- aprepitant
- - Emend - cancer chemotherapy (New drug) 27(2) 76-9
- - in cancer chemotherapy (PBAC question) 28(5) 119
- granisetron - Kytril (New drug) 27(4) 101-5

antiepileptics - see anticonvulsants**antifungal drugs**

- butoconazole nitrate - Gynazole - candidal vulvovaginitis (New drug) 29(5) 138-43
- posaconazole - Noxafil (New drug) 29(3) 84-7

antihistamines - see histamine**antihypertensives**

- ACE inhibitors vs diuretics 27(4) 98-101
- beta blockers 30(1) 5-7
- - letter 30(3) 59-63
- eplerenone - heart failure post-myocardial infarction - Inspra (New drug) 28(5) 130-1
- - letter 29(2) 32-5
- management of uncomplicated hypertension 28(2) 34-7
- - letter 28(5) 113-5
- moxonidine - Physiotens (New drug) 29(1) 25-7
- olmesartan medoxomil - Olmetec (New drug) 30(3) 79-82

antileukotriene drugs - see leukotriene receptor antagonists**antilipidaemic drugs**

- ezetimibe 27(5) 128
- fenofibrate
- - interactions with warfarin 29(6) 166
- - - letter 30(2) 32-4
- - Lipidil (New drug) 27(4) 101-5
- - and muscle symptoms 28(4) 102
- - letter 28(6) 136-9
- rosuvastatin - Crestor - hypercholesterolaemia (New drug) 29(6) 167-71

antimalarials - see malaria**antineoplastics**

- alemtuzumab - MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71
- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5
- aprepitant

- - as antiemetic in cancer chemotherapy (PBAC question) 28(5) 119
- - Emend - emetogenic chemotherapy (New drug) 27(3) 76-9
- bevacizumab - colorectal cancer - Avastin (New drug) 28(4) 104-6
- bortezomib - multiple myeloma - Velcade (New drug) 29(3) 84-7
- cetuximab - colorectal cancer - Erbitux (New drug) 28(4) 104-6
- chemotherapy and cancer survival rates (editorial) 29(1) 2-3
- dasatinib - Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55
- erlotinib - Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5
- fulvestrant - breast cancer - Faslodex (New drug) 30(4) 107-11
- lapatinib - breast cancer - Tykerb (New drug) 30(5) 133-5
- leukaemia in adults 29(3) 76-9
- methyl-5-aminolevulinate - skin cancer - Metvix (New drug) 27(3) 76-9
- neurocognitive effects of chemotherapy 31(1) 22-4
- palifermin - Kepivance - oral mucositis prevention in chemotherapy (New drug) 28(6) 156-8
- pancreatic carcinoma 28(2) 42-4
- pemetrexed disodium - lung cancer, mesothelioma - Alimta (New drug) 28(1) 19-23
- renal cell cancer 29(6) 151-3
- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71
- sunitinib - Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71
- taxanes and breast cancer (PBAC question) 30(1) 24-5
- antipsychotics**
- in bipolar disorders 30(3) 70-3
- costs and benefits of atypical vs typical antipsychotics 27(6) 146-9; 27(6) 149-51
- long-term community management of psychotic disorders 30(2) 44-6
- management of behavioural problems in dementia 28(3) 67-70
- neutropenia with quetiapine (medicinal mishap) 31(1) 10-11
- in pregnancy and breastfeeding 30(6) 162-3
- risk of diabetes 27(5) 118-9
- ziprasidone - Zeldox (New drug) 30(2) 50-55
- - letter 30(3) 59-63
- antivenoms**
- management of injuries by sea creatures 30(5) 117-21
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8

antiviral drugs - see also acyclovir;

- ganciclovir**
- adefovir dipivoxil - hepatitis B - Hepsera (New drug) 27(6) 159-65
- atazanavir - HIV - Reyataz (New drug) 27(6) 159-65
- darunavir - HIV - Prezista (New drug) 30(3) 79-82
- emtricitabine - HIV - Emtriva (New drug) 28(2) 49-51
- enfuvirtide - HIV - Fuzeon (New drug) 27(6) 159-65
- entecavir - chronic hepatitis B - Baraclude (New drug) 29(5) 138-43
- fosamprenavir - HIV - Telzir (New drug) 28(1) 19-23
- hepatitis C 29(2) 36-9
- HIV infection 28(6) 146-9
- influenza prophylaxis (editorial) 30(2) 30-1
- telbivudine - chronic hepatitis B - Sebivo (New drug) 30(6) 163-7
- tipranavir - HIV - Aptivus (New drug) 30(4) 107-11

anxiety disorders

- treatment with antidepressants 28(4) 91-3

Apidra SoloStar

- see insulin glulisine 30(5) 133-5

APMA - see Australian Pharmaceutical Manufacturers Association

aprepitant

- antiemetic in cancer chemotherapy (PBAC question) 28(5) 119
- Emend - emetogenic cancer chemotherapy (New drug) 27(3) 76-9

Aptivus

- see tipranavir 30(4) 107-11

arachnidism

- management 29(6) 156-8

arrhythmia - see also atrial fibrillation

- amiodarone 28(6) 150-4

Arsorb

- see isosorbide mononitrate 27(1) 21-3

arthritis - see also osteoarthritis;

rheumatology

- adalimumab - Humira 27(4) 101-5
- anakinra - Kineret (New drug) 27(6) 159-65
- NSAIDs and cardiovascular disease (editorial) 29(4) 90-1
- rheumatoid
- - abatacept - Orencia (New drug) 30(6) 163-7
- - abnormal laboratory results - antibodies to cyclic citrullinated peptides 29(6) 162-4
- - tumour necrosis factor inhibitors 29(3) 67-70; 27(2) 43-6
- - - letter 28(1) 5-7
- articaïne with adrenaline**
- Septanest, Deltazine, Bucanest - dental anaesthesia (New drug) 28(1) 19-23
- - correction 28(2) 49-51

aspirin

- alcohol and gastric bleeding 28(1) 18-9
- - letter 28(4) 84-7
- antiplatelet therapy after coronary stents 30(4) 92-96
- in early management of acute stroke 27(5) 120-3

asthma

- ciclesonide - Alvesco - asthma prophylaxis (New drug) 28(4) 104-6
- combination inhalers 28(2) 26-8
- ibuprofen-induced 27(4) 87
- salmeterol - safety concerns (editorial) 29(5) 118-9
- starting corticosteroid therapy 29(3) 63-6

Atazanavir

- Reyataz - HIV infection (New drug) 27(6) 159-65

atenolol

- beta blockers in hypertension 30(1) 5-7
- - letter 30(3) 59-63

atomoxetine

- Strattera - attention deficit hyperactivity disorder (New drug) 27(4) 101-5

attention deficit hyperactivity disorder

- atomoxetine - Strattera (New drug) 27(4) 101-5
- psychotropic drugs for children in general practice 28(5) 116-8

AusPharm Consumer Health Watch

- publishing of drug evaluations (editorial) 29(5) 120
- - letter 30(2) 32-4

Australian Medicines Handbook

- book reviews 28(4) 93; 28(2) 41; 27(5) 113

Australian Prescriber

- 30th anniversary and history 28(5) 120-2
- - letter 29(2) 32-5
- declarations of conflict of interest (letter) 29(4) 91-3
- Editorial Executive Committee - chairman - valedication 28(5) 115
- information from the drug industry about new drugs 28(4) 103
- - letter 29(3) 59-62
- transparency of new drug information 30(1) 26-7
- website user surveys 30(1) 16

autoantibodies

- antibodies to cyclic citrullinated peptides in rheumatoid arthritis 29(6) 162-4

autoimmune diseases

- immunosuppressants 29(4) 102-8
- monoclonal antibodies 29(5) 130-3
- myasthenia gravis 30(6) 156-60

Avastin

- see bevacizumab 28(4) 104-6

avian influenza

- antiviral drugs and vaccination (editorial) 30(2) 30-1

Axit

- see mirtazapine 27(1) 21-3

azathioprine

- in myasthenia gravis 30(6) 156-60
- pharmacology of immunosuppressants 29(4) 99-101

azithromycin

- Zithromax IV (New formulation) 27(2) 50-1

B

balsalazide

- Colazide - ulcerative colitis (New drug) 28(4) 104-6
- - letter 29(2) 32-5

Baraclud

- see entecavir 29(5) 138-43

basal cell carcinoma

- methyl-5-aminolevulinic acid - Metvix (New drug) 27(3) 76-9

BCG vaccination

- tuberculosis
- - letters 27(2) 28-33

beclomethasone dipropionate

- corticosteroid therapy in asthma 29(3) 63-6

behaviour disorders

- attention deficit hyperactivity disorder
- - atomoxetine - Strattera (New drug) 27(4) 101-5
- management of dementia 28(3) 67-70
- psychotropic drugs for children in general practice 28(5) 116-8
- risperidone in dementia (RADAR comment) 28(3) 71

benzodiazepines

- temazepam capsules and injecting drug users 27(3) 58-9
- - letter 27(5) 109-13

beta agonists

- corticosteroid combination inhalers in asthma 28(2) 26-8
- salmeterol - safety concerns (editorial) 29(5) 118-9

beta blockers

- hypertension 30(1) 5-7
- - letter 30(3) 59-63
- metoprolol succinate - Toprol-XL (New formulation) 27(3) 76-9

bevacizumab

- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5
- Avastin - colorectal cancer (New drug) 28(4) 104-6
- in renal cell cancer 29(6) 151-3

bioavailability

- meals and medicines 29(2) 40-2

bioequivalence

- generic drugs 30(2) 41-3
- - letter 30(4) 88-90
- Marevan and Coumadin (letter) 30(2) 32-4

bipolar disorders

- bipolar I - ziprasidone - Zeldox (New drug) 30(2) 50-55
- - letter 30(3) 59-63
- drug therapy 30(3) 70-3

birth defects

- antidepressants in pregnancy 30(5) 125-7
- biochemical tests in pregnancy 29(2) 48-52
- isotretinoin in acne 28(3) 59-61
- metformin in pregnancy and lactation 30(3) 68-9

bisphosphonates

- avascular necrosis of the jaw (letter) 27(2) 28-33
- and osteonecrosis of the jaws 30(4) 96-7

bites and stings

- management of animal and human bites 29(1) 6-8
- - letters 29(3) 59-62
- sea creatures 30(5) 117-21
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8

bivalirudin

- Angiomax - percutaneous coronary intervention (New drug) 28(3) 75-9

bladder, overactive

- anticholinergic drugs 29(1) 22-4
- - letter 29(4) 91-3
- darifenacin hydrobromide - Enablex (New drug) 29(5) 138-43
- solifenacin succinate - Vesicare - (New drug) 29(5) 138-43
- tolterodine - Detrusitol (New drug) 28(2) 49-51

blood coagulation factors

- abnormal haematology results in children 27(3) 64-6
- factor VIII inhibitor bypassing fraction - FEIBA-NF - haemophilia (New drug) 30(2) 50-55

blood pressure - see antihypertensives; hypertension

blood transfusion

- guidelines 28(2) 45-7

blood volume

- pentastarch - hypovolaemia - Voluven (New drug) 30(4) 107-11

bortezomib

- Velcade - multiple myeloma (New drug) 29(3) 84-7

bowel

- preparation 28(1) 16-7

brain

- magnetic resonance imaging in neuroradiology 31(1) 18-20

breast cancer

- fulvestrant - Faslodex (New drug) 30(4) 107-11
- lapatinib - Tykerb (New drug) 30(5) 133-5
- taxanes (PBAC question) 30(1) 24-5

breastfeeding

- antidepressants 30(5) 125-7
- antipsychotics 30(6) 162-3
- 'Drugs and breastfeeding' (book review) 27(6) 154
- - metronidazole (letter) 28(2) 29-33
- metformin and diabetes 30(3) 68-9
- pethidine in labour pain 27(2) 34-5

bronchodilators

- in chronic obstructive pulmonary disease 30(3) 64-7
- - letter - alpha-1-antitrypsin deficiency 30(6) 140-41

bruxism

- psychotropic drugs and dentistry 30(4) 98-101

Bucanest

- see articaine 28(1) 19-23

budesonide

- combination inhalers in asthma 28(2) 26-8
- corticosteroid therapy in asthma 29(3) 63-6

butoconazole nitrate

- Gynazole - candidal vulvovaginitis (New drug) 29(5) 138-43

Byetta

- see exenatide 30(6) 163-7

C

C-reactive protein

- abnormal laboratory results 30(3) 74-6

cabergoline

- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21

caesarian section

- carbetocin - prevention of uterine atony - Duratocin (New drug) 30(4) 107-11

calcineurin inhibitors

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

calcium supplementation

- osteoporosis
- - letter 27(4) 82-3

cancer (see also antineoplastics and specific organs)

- angiogenesis inhibitors - pharmacology 29(1) 9-12; 29(1) 13-5
- chemotherapy and cancer survival rates (editorial) 29(1) 2-3
- iobenguane - MIBGen - adrenal tumour localisation (New drug) 27(5) 131-3
- neurocognitive effects of chemotherapy 31(1) 22-4
- oral mucositis prevention in chemotherapy - palifermin - Kepivance (New drug) 28(6) 156-8
- radiotherapy and xerostomia 29(4) 97-8
- - dental notes 29(4) 108
- - letters 30(1) 3-4

cancer chemotherapy - see antineoplastics

candidiasis

- butoconazole nitrate - Gynazole - candidal vulvovaginitis (New drug) 29(5) 138-43

carbamazepine

- in bipolar disorders 30(3) 70-3

carbetocin

- Duratocin - prevention of uterine atony after caesarian section (New drug) 30(4) 107-11

carcinoma, basal cell

- methyl-5-aminolevulinate - Metvix (New drug) 27(3) 76-9

carcinoma, renal cell - see renal cell carcinoma**cardiovascular disease**

- ACE inhibitors vs diuretics 27(4) 98-101
- antiretroviral therapy in HIV infection 28(6) 146-9
- diabetes
 - exercise 30(5) 130-3
- echocardiography 29(5) 134-8
 - letter 30(1) 3-4
- NSAIDs in rheumatology (editorial) 29(4) 90-1
- the polypill controversy (editorial) 28(4) 82-3

CARPA Standard Treatment Manual

- book review 27(1) 8

cefaclor

- Aclor (New brand) 27(1) 21-3
- Karlor (New brand) 27(5) 131-3

Cefazolin

- see cephalosporins

Celapram

- see citalopram 27(1) 21-3

celecoxib

- vascular effects of COX-2 selective inhibitors 27(6) 142-5
 - letter 28(2) 29-33

cell markers

- abnormal laboratory results 30(5) 128-9

cephalexin

- Ialex (New brand) 27(5) 131-3

cephalosporins

- penicillin allergy 30(1) 25-6

cephazolin

- cefazolin (New formulation) 27(6) 159-65

Ceprotin

- see protein C 30(2) 50-55

cerebrovascular disorders

- beta blockers in hypertension 30(1) 5-7
 - letter 30(3) 59-63
- early management of acute stroke 27(5) 120-3
- magnetic resonance imaging in neuroradiology 31(1) 18-20

Certican

- see everolimus 28(3) 75-9

Cervarix

- human papillomavirus vaccine 30(5) 133-5

cervical cancer

- human papillomavirus vaccine - Cervarix (New drug) 30(5) 133-5
- human papillomavirus vaccine - Gardasil (New drug) 29(5) 138-43

cetuximab

- Erbitux - colorectal cancer (New drug) 28(4) 104-6

Champix

- see varenicline 31(1) 24-7

chelating agents

- deferasirox - Exjade - iron overload (New drug) 29(4) 112-5

chemotherapy, cancer - see antineoplastics**chest X-rays**

- Pocket guide (book review) 27(6) 158

chickenpox

- varicella vaccine - frequently asked questions 28(1) 2-5
 - letters 28(5) 113-5; 28(3) 55-8

children (see also infants)

- abnormal haematology laboratory results 27(3) 64-6
- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- antidepressants and suicide risk (editorials) 28(5) 110-1; 28(5) 111-3
 - letter 29(2) 32-5
- diagnosis and management of vulvovaginitis 28(4) 88-90
- drug regulation and prescribing (editorial) -- letter 27(2) 28-33
- 'Drugs and breastfeeding' (book review) 27(6) 154
 - metronidazole (letter) 28(2) 29-33
- fever - paracetamol
 - ibuprofen in fever (letter) 27(3) 55-7
- managing painful paediatric procedures 29(4) 94-6
 - dental notes 29(4) 108
 - letters 29(6) 149-50
- overdoses of over-the-counter drugs in infantile colic 29(3) 83
- over-the-counter medications
 - overdoses of anticholinergic drugs in infantile colic 29(3) 83
- psychotropic drugs for children in general practice 28(5) 116-8
- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5
- withdrawal of antiepileptic drugs from seizure-free children 29(1) 18-21

Chinese medicines

- quality and safety
 - letter 27(2) 28-33

chiral drugs

- pharmacology and efficacy 27(2) 47-9
 - correction 28(3) 55-8
 - letter 27(5) 109-13

Chirocaine

- see levobupivacaine 27(5) 131-3

chlamydia

- abnormal laboratory results 30(1) 8-13

chlorpromazine

- in pregnancy and breastfeeding 30(6) 162-3

cholera

- inactivated cholera vaccine - Dukoral (New drug) 27(6) 159-65

chronic obstructive pulmonary disease - see pulmonary disease**ciclesonide**

- Alvesco - asthma prophylaxis (New drug) 28(4) 104-6
- corticosteroid therapy in asthma 29(3) 63-6

cinacalcet

- Sensipar - hyperparathyroidism, hypercalcaemia (New drug) 28(3) 75-9

ciprofloxacin

- and fever (letter) 28(6) 136-9

citalopram

- Celapram (New strength) 27(1) 21-3
- serotonin syndrome (medicinal mishap) 29(3) 71

clinical pharmacology - see pharmacology**clinical tests - see abnormal laboratory results; diagnostic tests****clinical trials**

- appraising medical research 29(5) 122-4
- development of new prescription drugs 29(6) 159-61
- interpreting risks and ratios 31(1) 12-6
- pharmacotherapy for risk factors 30(2) 47-50
- risk factor pharmacotherapy (letter) 30(4) 88-90

Clonac

- see diclofenac sodium 27(1) 21-3

clopidogrel

- antiplatelet therapy after coronary stents 30(4) 92-96

Clopine

- see clozapine 27(1) 21-3

clozapine

- Clopine (New strength) 27(1) 21-3

cocaine

- adverse effects 29(4) 109-11

cognition

- neurocognitive effects of chemotherapy 31(1) 22-4

cognitive behaviour therapy

- depression in medical illness 30(4) 86-8
- management of mild depression in general practice 28(1) 8-10
- treatment of non-depressive disorders 28(4) 91-3

cognitive testing

- mental status testing in dementia 28(1) 11-3

Colazide

- see balsalazide 28(4) 104-6
- - letter 29(2) 32-5

colchicine

- management of gout 27(1) 10-3

colic, infantile

- overdoses of over-the-counter anticholinergic drugs 29(3) 83

colitis, ulcerative

- balsalazide - Colazide (New drug) 28(4) 104-6
- - letter 29(2) 32-5

colonic diseases

- bowel preparation 28(1) 16-7

colonoscopy

- bowel preparation 28(1) 16-7

colorectal cancer

- angiogenesis inhibitors 29(1) 13-5
- bevacizumab - Avastin (New drug) 28(4) 104-6
- cetuximab - Erbitux (New drug) 28(4) 104-6

combination products

- the polypill and cardiovascular disease (editorial) 28(4) 82-3

complementary medicines

- 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91
- - letter 30(6) 140-41
- Chinese medicines - quality and safety
- - letter 27(2) 28-33
- efficacy of Ginkgo biloba in tinnitus (editorial) 29(5) 120
- - letter 30(2) 32-4
- glucosamine in osteoarthritis of the knee 27(3) 61-3
- - letter 27(5) 109-13
- regulation of advertising 27(5) 124-7

compliance - see patient compliance**computerised prescribing systems - see electronic prescribing****Concerta**

- see methylphenidate 27(2) 50-1

confidence intervals

- interpreting risks and ratios 31(1) 12-6

congenital abnormalities - see birth defects**congestive heart failure - see heart failure, congestive****conjunctivitis**

- ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23

Conn's syndrome

- see abnormal laboratory results 30(6) 147-9

consumer - see also patient**consumer information**

- Aboriginal patients 28(5) 123-5
- Adverse Medicine Events Line 28(4) 102; 27(2) 38
- aspirin and alcohol 28(1) 18-9
- - letter 28(4) 84-7
- Consumer Medicine Information
- - utilisation 30(5) 122-4

- direct-to-consumer advertising 27(1) 4-6
 - drug labelling and packaging (letter) 28(1) 5-7
 - - letter 28(4) 84-7
 - 'Health care and notions of risk' (book review) 27(6) 159
 - Media Doctor 28(1) 13
 - overseas travel and medicines 29(3) 80-2
 - pharmacotherapy for risk factors 30(2) 47-50
 - publishing of drug evaluations (editorial) 29(5) 120
 - - letter 30(2) 32-4
 - quality use of generic drugs (editorial) 27(4) 80-1
 - - letters 28(2) 29-33; 27(6) 138-41
 - regulation of medicines advertising in Australia 27(5) 124-7
 - role of patient support organisations 27(1) 19-21
 - starter packs and drug samples 30(1) 14-16
- consumers (see also patient's perspective)**
- direct drug advertising
 - - in New Zealand (editorial) 29(2) 30-2
 - quality use of generic drugs (editorial) 27(4) 80-1

Continence Foundation of Australia

- patient support organisation 29(1) 24

contraceptives

- dienogest/ethinyloestradiol - Valette (New drug) 30(2) 50-55
- overseas travel and medicines 29(3) 80-2
- in polycystic ovary syndrome 27(5) 129-31
- - letter 28(3) 55-8

contrast media

- disodium gadoxetate - Primovist - liver imaging (New drug) 29(3) 84-7
- gadobenate dimeglumine - magnetic resonance imaging - MultiHance (New drug) 27(6) 159-65
- perflutren - ultrasound - Definity (New drug) 30(4) 107-11

Copaxone

- see glatiramer 27(5) 131-3

COPD - also see pulmonary disease,**chronic obstructive**

- in primary care - book review 27(1) 13

Corolan

- see ivabradine 30(2) 50-55

coronary disease (see also angina; myocardial infarction)

- antiplatelet therapy after coronary stents 30(4) 92-96

coronary intervention, percutaneous

- antiplatelet therapy after coronary stents 30(4) 92-96
- bivalirudin - anticoagulant - Angiomax (New drug) 28(3) 75-9

corticosteroids

- in asthma 29(3) 63-6
- beta agonist combination inhalers in asthma 28(2) 26-8

- in chronic obstructive pulmonary disease 30(3) 64-7
- - letter - alpha-1-antitrypsin deficiency 30(6) 140-41
- ciclesonide - Alvesco - asthma prophylaxis (New drug) 28(4) 104-6
- pharmacology of immunosuppressants 29(4) 102-8

cortisol

- abnormal laboratory results 30(6) 147-9

cost of drugs

- drug price reforms (editorial) 30(6) 138-40
- funding of influenza vaccination for healthy adults 30(2) 35-7
- - letter 30(5) 116
- top 10 drugs 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37

cost-effectiveness of drugs

- atypical antipsychotics 27(6) 149-51
- expensive drugs and the Pharmaceutical Benefits Scheme (editorial) 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8
- - letter 28(3) 55-8

counselling

- management of mild depression in general practice 28(1) 8-10

Coversyl

- see perindopril erbumine 27(2) 50-1

cramp

- magnesium (letter) 30(6) 140-41

creatinine clearance

- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4

Crestor

- see rosuvastatin 29(6) 167-71

Curosurf

- see poractant alfa 28(3) 75-9

Cushing's syndrome

- abnormal laboratory results 30(6) 147-9

cyclo-oxygenase inhibitors

- lumiracoxib - Prexige (New drug) 29(1) 25-7
- safety of new drugs (editorial) 28(3) 54-5
- vascular effects of COX-2 selective inhibitors 27(6) 142-5
- - letters 28(2) 29-33; 28(2) 29-33; 28(2) 29-33

cyclosporin

- pharmacology of immunosuppressants 29(4) 99-101

cytotoxic drugs - see antineoplastics

D

darifenacin hydrobromide

- Enablex - overactive bladder (New drug) 29(5) 138-43

darunavir

- Prezista - HIV infection (New drug) 30(3) 79-82

dasatinib

- Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55

decision-support software - see electronic prescribing**deep venous thrombosis - see thromboembolism****deferasirox**

- Exjade - iron overload (New drug) 29(4) 112-5

Definity

- see perflutren 30(4) 107-11

Deltazine

- see articaine 28(1) 19-23

dementia

- donepezil - Alzheimer's disease (editorial) 28(6) 134-5
- management of behavioural problems 28(3) 67-70
- mental status testing 28(1) 11-3
- patient support organisations 28(3) 72
- risperidone for behavioural disturbances (RADAR comment) 28(3) 71

dental anaesthesia

- articaine with adrenaline - Septanest, Deltazine, Bucanest (New drug) 28(1) 19-23

dental implications - see dental notes**dental notes**

- adverse reaction reporting 28(6) 142
- antibiotics for surgical prophylaxis 28(2) 41
- - letters 28(5) 113-5; 28(3) 55-8
- antiretroviral therapy in HIV infection 28(6) 149
- bioequivalence of generic drugs 30(2) 43
- drug promotion and dentistry 30(6) 153
- emergency drugs in dentistry 30(6) 146
- herpes simplex infections 30(1) 13
- influenza vaccination for healthy adults 30(2) 37
- management of hepatitis C 29(2) 52
- - letter 30(3) 59-63
- managing painful paediatric procedures 29(4) 108
- myasthenia gravis 30(6) 160
- neuropathic pain, drug treatment 29(3) 82
- warfarin and dental patients
- - letters 27(1) 3
- xerostomia 29(4) 108

dental pain

- management 30(3) 77-9

dentistry

- bisphosphonates
- - and avascular necrosis of the jaw (letter) 27(2) 28-33
- - and osteonecrosis of the jaws 30(4) 96-7
- dizziness and prolonged dental treatment (letter) 28(6) 136-9

- drugs and gingival bleeding 29(6) 154-5
- echocardiography and endocarditis (letter) 30(1) 3-4
- periodontitis and diabetes 27(2) 36-8
- and psychotropic drugs 30(4) 98-101
- Therapeutic Guidelines - Oral and Dental (book review) 30(4) 106

depression (see also antidepressant drugs)

- antidepressants and suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5
- antidepressants in pregnancy and breastfeeding 30(5) 125-7
- management of mild depression in general practice 28(1) 8-10
- in medical illness 30(4) 86-8

dermatitis

- diagnosis and management of vulvovaginitis in childhood 28(4) 88-90

dermatitis, atopic

- pimecrolimus - Elidel (New drug)
- - letter 27(2) 28-33

dermatology

- Therapeutic Guidelines (book review) 28(2) 44

Detrusitol

- see tolterodine 28(2) 49-51

developing countries

- expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8

dextromethorphan

- precipitating serotonin syndrome 29(3) 71
- - letter 29(6) 149-50

diabetes

- antipsychotic drugs and risk of diabetes 27(5) 118-9
- exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7
- exercise 30(5) 130-3
- - letter 31(1) 3-4
- foot infections 30(1) 21-4
- insulin detemir - Levemir FlexPen (New drug) 28(5) 130-1
- insulin glargine - Lantus (New drug) 27(2) 50-1
- - letter 27(6) 138-41
- insulin glulisine - Apidra SoloStar (New drug) 30(5) 133-5
- insulin therapy and hypoglycaemic drugs 27(4) 93-6
- metformin in pregnancy and lactation 30(3) 68-9
- overseas travel and insulin 29(3) 80-2
- patient support organisations 27(4) 96-7
- and periodontitis 27(2) 36-8
- pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9
- thiazolidinedione pharmacology 27(3) 67-70; 27(3) 70-4

diabetes, gestational

- metformin in pregnancy and lactation 30(3) 68-9

diagnostic tests (see also abnormal laboratory results)

- echocardiography 29(5) 134-8
- - letter 30(1) 3-4
- magnetic resonance imaging in neuroradiology 31(1) 18-20
- mental status testing in dementia 28(1) 11-3
- oximetry
- - nail polish removal (letter) 27(2) 28-33
- recurrent deep venous thrombosis 30(2) 38-40

diclofenac sodium

- Clonac (New brand) 27(1) 21-3

dienogest/ethinylestradiol

- Valette - contraceptive (New drug) 30(2) 50-55

diet

- management of obesity 29(2) 43-7

digoxin

- brands and dosages 29(6) 153
- - letter 30(2) 32-4

diphtheria, tetanus and pertussis vaccine

- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b
- - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65

discharge medication

- information and prescriptions (editorial) 29(3) 58-9
- - letters 29(5) 121

disease outbreaks

- antiviral drugs and influenza prophylaxis 30(2) 30-1

disodium gadoxetate

- Primovist - liver imaging (New drug) 29(3) 84-7

diuretics

- drug-induced hyponatraemia
- - letters 27(2) 28-33
- vs ACE inhibitors in hypertension 27(4) 98-101

dizziness

- diagnosis and management 28(4) 94-7
- - dental treatment (letter) 28(6) 136-9

docetaxel

- breast cancer (PBAC question) 30(1) 24-5

doctor's bag

- see emergency supplies 30(6) 143-6

domiciliary services

- chronic obstructive pulmonary disease 30(3) 64-7

donepezil

- Alzheimer's disease (editorial) 28(6) 134-5
- - letter 29(3) 59-62

dopamine agonists

- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21
- quinagolide - hyperprolactinaemia - Norprolac (New drug) 28(6) 156-8

Down's syndrome

- biochemical tests in pregnancy 29(2) 48-52

drug abuse

- 'Drugs of abuse' (book review) 29(1) 8
- psychostimulant poisoning 29(4) 109-11

drug bulletins - see drug information**drug costs - see cost of drugs****drug dependence**

- temazepam capsules and injecting drug users 27(3) 58-9
- - letter 27(5) 109-13

drug evaluation

- appraising medical research 29(5) 122-4
- development of new prescription drugs 29(6) 159-61
- freedom of publication (editorial) 29(5) 120
- - letter 30(2) 32-4
- interpreting risks and ratios in clinical trials 31(1) 12-6
- Therapeutic Goods Administration approval processes 27(6) 156-8
- transparency of information about new drugs
- - editorial 28(4) 83-4
- - transparency rating 30(1) 26-7; 28(4) 103
- - - letter 29(3) 59-62

drug industry (see also advertising)

- 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91
- chiral drugs 27(2) 47-9
- - correction 28(3) 55-8
- - letter 27(5) 109-13
- development of new prescription drugs 29(6) 159-61
- direct-to-consumer advertising 27(1) 4-6
- - in New Zealand (editorial) 29(2) 30-2
- drug promotion and health professionals 30(6) 150-3
- effectiveness of new drugs (editorial) 27(1) 2-3
- - letter 27(3) 55-7
- expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8
- - letter 28(3) 55-8
- gabapentin promotion and off-label prescribing
- - letters 27(4) 82-3
- Medicines Australia
- - code of conduct breaches 30(6) 153-5; 29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(3) 60; 27(1) 6-7
- - - vardenafil 30(6) 154
- 'Medicines out of control?' (book review) 27(5) 117
- patent evergreening (editorial) 29(6) 148-9
- 'Powerful medicines' (book review) 28(4) 101
- publishing of drug evaluations (editorial) 29(5) 120
- - letter 30(2) 32-4
- quality use of generic drugs (editorial) 27(4) 80-1

- - letters 28(2) 29-33; 27(6) 138-41
- regulation of advertising 27(5) 124-7
- retail pharmacy promotions (letters) 27(2) 28-33
- safety and withdrawal of COX inhibitors (editorial) 28(3) 54-5
- starter packs and adverse effects 30(1) 14-16
- transparency of information about new drugs
- - editorial 28(4) 83-4
- - transparency rating 30(1) 26-7; 28(4) 103
- - - letter 29(3) 59-62
- US Free Trade Agreement (editorial) 27(3) 54-5
- - letter 27(5) 109-13

drug information

- AdWatch website review 27(3) 63
- Australian Medicines Handbook
- - book reviews 28(4) 93; 28(2) 41; 27(5) 113
- Australian Prescriber
- - 30th anniversary and history 28(5) 120-2
- - - letter 29(2) 32-5
- Consumer Medicine Information 30(5) 122-4
- declarations of conflict of interest (letter) 29(4) 91-3
- direct-to-consumer advertising 27(1) 4-6
- drug labelling and packaging (letter) 28(1) 5-7
- - letter 28(4) 84-7
- effectiveness of new drugs (editorial) 27(1) 2-3
- - letter 27(3) 55-7
- Goodman & Gilman's 'The pharmacological basis of therapeutics' (book review) 29(1) 25
- hospital discharge medication (editorial) 29(3) 58-9
- - letters 29(5) 121
- Media Doctor 28(1) 13
- MedSafety online learning system for medication error prevention (letter) 27(5) 109-13
- publishing of drug evaluations (editorial) 29(5) 120
- - letter 30(2) 32-4
- Therapeutic Guidelines
- - book reviews
- - - Dermatology 28(2) 44
- - - Endocrinology 28(3) 58
- - - Psychotropic 27(2) 50
- - PDA review - Mini TG (personal digital assistant version) 29(1) 21
- transparency of information about new drugs
- - editorial 28(4) 83-4
- - transparency rating 30(1) 26-7; 28(4) 103
- - - letter 29(3) 59-62

drug interactions

- antiretroviral therapy in HIV infection 28(6) 146-9
- Chinese medicines
- - letter 27(2) 28-33
- depression in medical illness 30(4) 86-8
- meals and medicines 29(2) 40-2
- polypharmacy (editorial) 31(1) 2-3
- psychotropic drugs and dentistry 30(4) 98-101
- serotonin syndrome with dextromethorphan and citalopram 29(3) 71
- tramadol 27(2) 26-7
- warfarin
- - fenofibrate 29(6) 166
- - - letter 30(2) 32-4

drug labelling

- aspirin and alcohol 28(1) 18-9
- - letter 28(4) 84-7
- consumer information - drug packaging (letters) 28(4) 84-7; 28(1) 5-7
- generic drug names (letter) 28(2) 29-33

drug prescribing - see drug therapy; drug utilisation; electronic**drug promotion - see advertising****drug regulation**

- adverse reaction reporting 28(6) 140-2
- advertising 27(5) 124-7
- - direct-to-consumer advertising in New Zealand (editorial) 29(2) 30-2
- - efficacy of Ginkgo biloba in tinnitus (letter) 30(2) 32-4
- drug promotion and health professionals 30(6) 150-3
- pitfalls of prescribing generic drugs (letter) 28(4) 84-7
- quality use of generic drugs (editorial) 27(4) 80-1
- - letter 28(2) 29-33; 27(6) 138-41
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5
- safety and withdrawal of COX inhibitors (editorial) 28(3) 54-5
- starter packs and drug samples 30(1) 14-16
- Therapeutic Goods Administration approval processes 29(6) 159-61; 27(6) 156-8
- transparency of information about new drugs
- - editorial 28(4) 83-4
- - two-way transparency 30(1) 26-7; 28(4) 103
- - - letter 29(3) 59-62
- US Free Trade Agreement (editorial) 27(3) 54-5
- - letter 27(5) 109-13

drug samples

- starter packs and adverse effects 30(1) 14-16

drug therapy (items relating to drugs generally)

- Aboriginal patients 28(5) 123-5
- - letters 29(6) 149-50; 29(3) 59-62
- Aboriginal people - National Medicines Policy
- - letter 27(3) 55-7
- advice for overseas travellers 29(3) 80-2
- bioequivalence of generic drugs 30(2) 41-3
- - letter 30(4) 88-90
- children and off-label prescribing (editorial)
- - letter 27(2) 28-33
- competency for non-medical prescribers (editorial) 30(3) 58-9
- Consumer Medicine Information 30(5) 122-4
- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4
- evidence-based medicine (editorial) 30(5) 114-5
- expensive drugs and the Pharmaceutical Benefits Scheme (editorial) 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs (editorials) 27(6) 136-7; 27(6) 137-8
- - letter 28(3) 55-8
- hospital discharge - medication information and prescriptions (editorial) 29(3) 58-9
- - letters 29(5) 121
- meals and medicines 29(2) 40-2
- MedSafety online learning system for medication error prevention (letter) 27(5) 109-13
- nurse prescribing
- - editorial 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90
- pharmacotherapy for risk factors 30(2) 47-50
- polypharmacy (editorial) 31(1) 2-3
- prescribing and the law (editorial) 27(5) 108-9
- - letter 28(2) 29-33
- risk factor pharmacotherapy (letter) 30(4) 88-90
- starter packs and adverse effects 30(1) 14-16
- drug utilisation**
- over-the-counter medications and children
- - letters 27(2) 28-33
- prevention of antibiotic resistance 27(2) 39-42
- - letter 27(6) 138-41
- statistics - top 10 drugs 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37
- drugs in sport**
- anti-doping code 27(4) 84-7
- Dukoral**
- see cholera vaccine 27(6) 159-65

Duratocin

- see carbetocin 30(4) 107-11

dyspepsia

- proton pump inhibitors - long-term management 31(1) 5-7

E

eating disorders

- treatment with antidepressants 28(4) 91-3

echocardiography

- diagnostic tests 29(5) 134-8
- - letter 30(1) 3-4
- perflutren - contrast medium - Definity (New drug) 30(4) 107-11

ecstasy

- adverse effects 29(4) 109-11

editorials

- antidepressants
- - suicide risk in children 28(5) 110-1; 28(5) 111-3
- - - letter 29(2) 32-5
- antiviral drugs and influenza prophylaxis 30(2) 30-1
- chemotherapy and cancer survival rates 29(1) 2-3
- children and off-label prescribing
- - letter 27(2) 28-33
- competency for non-medical prescribers 30(3) 58-9
- depression in medical illness 30(4) 86-8
- direct-to-consumer advertising in New Zealand (editorial) 29(2) 30-2
- donepezil in Alzheimer's disease 28(6) 134-5
- - letter 29(3) 59-62
- drug patent evergreening 29(6) 148-9
- effectiveness of new drugs 27(1) 2-3
- - letter 27(3) 55-7
- evidence-based medicine - turning knowledge into action 30(5) 114-5
- expensive drugs and the Pharmaceutical Benefits Scheme 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs 27(6) 136-7; 27(6) 137-8
- - letter 28(3) 55-8
- freedom of publication of drug evaluations 29(5) 120
- - letters 30(2) 32-4
- hospital discharge - medication information and prescriptions 29(3) 58-9
- - letters 29(5) 121
- NSAIDs and cardiovascular disease in rheumatology 29(4) 90-1
- nurse prescribing 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90
- Pharmaceutical Benefits Scheme drug price reforms 30(6) 138-40
- polypharmacy 31(1) 2-3
- the polypill and cardiovascular disease 28(4) 82-3

- prescribing and the law 27(5) 108-9
- - letters 28(2) 29-33; 28(2) 29-33
- quality use of generic drugs 27(4) 80-1
- - letters 28(2) 29-33; 27(6) 138-41
- safety and withdrawal of COX inhibitors 28(3) 54-5
- salmeterol - safety concerns 29(5) 118-9
- selective serotonin reuptake inhibitors and suicide risk in children 28(5) 111-3
- - letter 29(2) 32-5
- tramadol adverse effects 27(2) 26-7
- transparency of information about new drugs (editorial) 28(4) 83-4
- US Free Trade Agreement and pharmaceuticals 27(3) 54-5
- - letter 27(5) 109-13
- withdrawal of drugs from market
- - letters 27(2) 28-33
- efalizumab**
- Raptiva - psoriasis (New drug) 28(1) 19-23
- eflornithine hydrochloride**
- Vaniqa - facial hair reduction (New drug) 29(3) 84-7
- eformoterol**
- combination inhalers in asthma 28(2) 26-8
- electrocardiography**
- 'Pocket guide to ECGs' (book review) 29(4) 93
- Elidel**
- see pimecrolimus 27(2) 28-33
- Eligard**
- see leuprorelin 27(2) 50-1
- Emend**
- see aprepitant 27(3) 76-9
- emergency medicine**
- Australian Medicines Handbook - book review 28(2) 41
- emergency supplies**
- emergency drugs - doctor's bag supplies 30(6) 143-6
- emergency drugs in dentistry 30(6) 146
- emtricitabine**
- Emtriva - HIV infection (New drug) 28(2) 49-51
- Emtriva**
- see emtricitabine 28(2) 49-51
- Enablex - see darifenacin hydrobromide enantiomers**
- pharmacology and efficacy 27(2) 47-9
- - correction 28(3) 55-8
- - letter 27(5) 109-13
- endocrinology**
- Therapeutic Guidelines - book review 28(3) 58
- endoscopy**
- management of gastrointestinal haemorrhage 28(3) 62-6
- enfuvirtide**
- Fuzeon - HIV infection (New drug) 27(6) 159-65

entecavir

- Baraclude - chronic hepatitis B (New drug) 29(5) 138-43

epidemics

- see disease outbreaks 30(2) 30-1

epilepsy

- pregabalin - Lyrica (New drug) 28(3) 75-9
- withdrawal of antiepileptic drugs in seizure-free adults 27(5) 114-7
- withdrawal of drugs from seizure-free children 29(1) 18-21

EpiPen

- see adrenaline 29(2) 52-3; 28(4) 90

eplerenone

- Inspra - heart failure postmyocardial infarction (New drug) 28(5) 130-1
- letter 29(2) 32-5

epoetin beta

- NeoRecormon - anaemia (New drug) 29(4) 112-5

Erbix

- see cetuximab 28(4) 104-6

erlotinib

- Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5

erythrocyte sedimentation rate

- C-reactive protein - abnormal laboratory results 30(3) 74-6

erythropoietin

- epoetin beta - NeoRecormon - anaemia (New drug) 29(4) 112-5

escitalopram oxalate

- antidepressant - Lexapro (New drug)
- letter 27(2) 28-33
- chiral drugs - pharmacology and efficacy 27(2) 47-9

esomeprazole

- chiral drugs - pharmacology and efficacy 27(2) 47-9
- gastrointestinal haemorrhage (letter) 28(6) 136-9
- Nexium IV (New formulation) 27(6) 159-65

etanercept

- rheumatoid arthritis 27(2) 43-6
- tumour necrosis factor blockers in rheumatology 29(3) 67-70

ethics

- drug promotion and health professionals 30(6) 150-3

ethinyloestradiol

- dienogest combination - contraceptive - Valette (New drug) 30(2) 50-55

evergreening

- drug patents (editorial) 29(6) 148-9

everolimus

- Certican - transplantation (New drug) 28(3) 75-9
- pharmacology of immunosuppressants 29(4) 99-101

evidence-based medicine

- appraising medical research 29(5) 122-4
- online information services and general practice 27(1) 16-8
- pharmacotherapy for risk factors 30(2) 47-50
- letter 30(4) 88-90
- turning knowledge into action (editorial) 30(5) 114-5

exenatide

- type 2 diabetes - Byetta (New drug) 30(6) 163-7

exercise

- diabetes 30(5) 130-3
- letter 31(1) 3-4

exercise testing

- diabetes 30(5) 130-3
- letter 31(1) 3-4

Exjade

- see deferasirox 29(4) 112-5

experimental pharmacology - see pharmacology**eye - see also specific diseases**

- eye drops, correct use 31(1) 16-17

ezetimibe

- RADAR comment 27(5) 128

Ezetrol

- see ezetimibe 27(5) 128

F

Fabrazyme

- see agalsidase beta 27(5) 131-3

Fabry's disease

- agalsidase alfa - Replagal (New drug) 27(5) 131-3
- agalsidase beta - Fabrazyme (New drug) 27(5) 131-3

factor VIII

- inhibitor bypassing fraction - FEIBA-NF - haemophilia (New drug) 30(2) 50-55

Faslodex

- see fulvestrant 30(4) 107-11

Fasturtec

- see rasburicase 27(6) 159-65

FEIBA-NF

- see factor VIII inhibitor bypassing fraction 30(2) 50-55

fenofibrate

- Lipidil - dyslipidaemia (New drug) 27(4) 101-5
- warfarin interactions 29(6) 166
- letter 30(2) 32-4

fever

- in children - ibuprofen (letter) 27(3) 55-7
- and ciprofloxacin (letter) 28(6) 136-9

fibrinolytic drugs

- in early management of acute stroke 27(5) 120-3

fish

- management of puncture injuries 30(5) 117-21

fish oil

- NSAIDs in rheumatology (editorial) 29(4) 90-1

flow cytometry

- abnormal laboratory results 30(5) 128-9

Fluad

- see influenza vaccine 27(2) 50-1

fluoxetine

- selective serotonin reuptake inhibitors and suicide risk in children (editorial) 28(5) 111-3
- letter 29(2) 32-5

fluticasone

- combination inhalers in asthma 28(2) 26-8
- corticosteroid therapy in asthma 29(3) 63-6

food

- isomaltulose - sugar substitute - warning in fructose metabolism disorders (letter) 31(1) 3-4
- meals and medicines 29(2) 40-2

foot infections

- in diabetes 30(1) 21-4

formularies

- Australian Medicines Handbook - book reviews 28(4) 93; 28(2) 41; 27(5) 113

Forteo

- see teriparatide 27(5) 109-13; 27(1) 21-3

fosamprenavir

- Telzir - HIV infection (New drug) 28(1) 19-23

Fosrenol

- see lanthanum carbonate 29(2) 53-5

Free Trade Agreement

- US Free Trade Agreement and the drug industry (editorial) 27(3) 54-5
- letter 27(5) 109-13

fructose metabolism disorders

- warning about isomaltulose sugar substitute (letter) 31(1) 3-4

fulvestrant

- Faslodex - breast cancer (New drug) 30(4) 107-11

fungal infections

- posaconazole - Noxafil (New drug) 29(3) 84-7

Fuzeon

- see enfuvirtide - HIV infection 27(6) 159-65

G

gabapentin

- Nupentin (New brand) 27(5) 131-3
- promotion and off-label prescribing
- letters 27(4) 82-3

gadobenate dimeglumine

- MultiHance - magnetic resonance imaging - contrast agent (New drug) 27(6) 159-65

gadoxetate disodium

- Primovist - liver imaging (New drug) 29(3) 84-7

galantamine

- Reminyl (New formulation) 27(4) 101-5

Gardasil - see human papillomavirus vaccine**gastro-oesophageal reflux disease**

- proton pump inhibitors
- - long-term management 31(1) 5-7

gastroenteritis

- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5

gastroenterology

- Therapeutic Guidelines - book reviews 30(2) 46

gastrointestinal haemorrhage

- aspirin and alcohol 28(1) 18-9
- - letter 28(4) 84-7
- management 28(3) 62-6
- - letter 28(6) 136-9
- paracetamol adverse effects (letter) 30(3) 59-63

gastrointestinal stromal tumour

- sunitinib - Sutent (New drug) 29(6) 167-71

gemcitabine

- pancreatic carcinoma 28(2) 42-4

general practice

- drugs for the doctor's bag 30(6) 143-6
- management of mild depression 28(1) 8-10
- online information services 27(1) 16-8
- prescribing and the law (editorial) 27(5) 108-9
- - letters 28(2) 29-33
- psychotropic drugs for children and adolescents 28(5) 116-8
- smoking cessation guidelines 28(3) 73-5
- - letter 28(6) 136-9

generic drugs

- bioequivalence
- - and pharmacokinetics 30(2) 41-3
- - - letters 30(4) 88-90
- patent evergreening (editorial) 29(6) 148-9
- Pharmaceutical Benefits Scheme drug price reforms (editorial) 30(6) 138-40
- pitfalls of prescribing generics (letter) 28(4) 84-7
- quality use (editorial) 27(4) 80-1
- - letters 28(2) 29-33; 27(6) 138-41

geriatric - see aged**gingival enlargement**

- drug-induced 29(6) 154-5

gingivitis

- and diabetes 27(2) 36-8

Ginkgo biloba

- efficacy in tinnitus (editorial) 29(5) 120
- - letter 30(2) 32-4

glatiramer

- Copaxone (New formulation) 27(5) 131-3

glitazones

- see thiazolidinediones 27(3) 67-70; 27(3) 70-4

glomerular filtration rate

- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4

glucosamine

- and osteoarthritis (PBAC question) 28(2) 48
- in osteoarthritis of the knee 27(3) 61-3
- - letter 27(5) 109-13

gonorrhoea

- abnormal laboratory results 30(1) 8-13

Gopten

- see trandolapril 27(6) 159-65

gout

- management 27(1) 10-3
- - letter 27(4) 82-3

granisetron

- Kytril - nausea and vomiting (New drug) 27(4) 101-5

guidelines (see also therapeutic guidelines)

- turning knowledge into action (editorial) 30(5) 114-5

gum disease - see periodontitis**Gynazole - see butoconazole nitrate**

H

haematology

- abnormal laboratory results in children 27(3) 64-6
- diagnostic immunology - abnormal laboratory results 30(5) 128-9

haematopoietic stem cell transplantation

- adult leukaemia 29(3) 76-9

haemodialysis

- iron sucrose - iron deficiency anaemia - Venofer (New drug) 28(2) 49-51
- - letter 28(4) 84-7

haemoglobin

- oximetry
- - nail polish removal (letter) 27(2) 28-33

haemophilia

- factor VIII inhibitor bypassing fraction - FEIBA-NF (New drug) 30(2) 50-55

Haemophilus influenzae type b

- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix hexa (New combination) 27(6) 159-65

hair growth reduction

- eflornithine hydrochloride - Vaniqa - facial hair (New drug) 29(3) 84-7

hay fever - see rhinitis, allergic**HDL cholesterol - see cholesterol****headache (see also migraine)**

- and analgesic overuse 28(6) 143-5
- - letter 29(3) 59-62

Healthy Skepticism

- AdWatch website review 27(3) 63

heart transplantation

- everolimus - Certican (New drug) 28(3) 75-9

heart valve diseases

- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21

Helicobacter pylori

- proton pump inhibitors - long-term management 31(1) 5-7

hepatitis B

- adefovir dipivoxil - Hepsera - (New drug) 27(6) 159-65
- entecavir - Baraclude (New drug) 29(5) 138-43
- telbivudine - Sebivo (New drug) 30(6) 163-7
- vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio - Infanrix penta (New combination) 27(6) 159-65
- vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b - Infanrix hexa 27(6) 159-65

hepatitis B vaccine

- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta and Infanrix hexa (New combinations) 27(6) 159-65

hepatitis C

- dental notes 29(2) 52
- - letter 30(3) 59-63
- management 29(2) 36-9
- patient support organisation 29(2) 39

Hepsera

- see adefovir dipivoxil 27(6) 159-65

herbal preparations (see also complementary medicines)

- Chinese medicines - quality and safety
- - letter 27(2) 28-33

herpes simplex

- genital herpes
- - abnormal laboratory results 30(1) 8-13
- - dental notes 30(1) 13

herpes zoster

- vaccine, Zostavax (New drug) 31(1) 24-7
- varicella vaccination (letter) 30(5) 116

HighWire Press

- online information services and general practice 27(1) 16-8

hirsutism

- eflornithine hydrochloride - Vaniqa - facial hair (New drug) 29(3) 84-7
- polycystic ovary syndrome 27(5) 129-31

histamine H1 blockers

- ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23

HIV/AIDS

- abnormal laboratory results 30(1) 8-13
- antiretroviral therapy 28(6) 146-9
- atazanavir - Reyataz (New drug) 27(6) 159-65
- darunavir - Prezista (New drug) 30(3) 79-82
- dental notes 28(6) 149
- emtricitabine - Emtriva (New drug) 28(2) 49-51

- enfuvirtide - HIV infection - Fuzeon (New drug) 27(6) 159-65
- fosamprenavir - Telzir (New drug) 28(1) 19-23
- tipranavir - Aptivus (New drug) 30(4) 107-11
- hospitals**
- discharge medication - information and prescriptions (editorial) 29(3) 58-9
- - letters 29(5) 121
- human chorionic gonadotrophin**
- biochemical tests for abnormalities in pregnancy 29(2) 48-52
- human papillomavirus vaccine**
- Cervarix (New drug) 30(5) 133-5
- Gardasil (New drug) 29(5) 138-43
- Humira**
- see adalimumab 27(4) 101-5
- hydromorphone**
- Palladone XL (New formulation) 28(3) 75-9
- hyoscine**
- adverse reaction reporting 28(6) 140-2
- hyperactivity disorder in children**
- psychotropic drugs for children in general practice 28(5) 116-8
- hyperaldosteronism**
- abnormal laboratory results 30(6) 147-9
- hypercalcaemia**
- cinacalcet - Sensipar (New drug) 28(3) 75-9
- hypercholesterolaemia**
- ezetimibe - Ezetrol (New drug)
- - in dyslipidaemia (RADAR comment) 27(5) 128
- fenofibrate - Lipidil (New drug) 27(4) 101-5
- rosuvastatin - Crestor (New drug) 29(6) 167-71
- hyperlipidaemia (see also antilipidaemic drugs)**
- ezetimibe in dyslipidaemia (RADAR comment) 27(5) 128
- fenofibrate - Lipidil (New drug) 27(4) 101-5
- hypermagnesaemia**
- abnormal laboratory results 30(4) 102-5
- hyperparathyroidism**
- cinacalcet - Sensipar (New drug) 28(3) 75-9
- hyperphosphataemia**
- lanthanum carbonate hydrate - chronic renal failure - Fosrenol (New drug) 29(2) 53-5
- sevelamer - chronic renal disease -Renagel (New drug) 28(6) 156-8
- hyperprolactinaemia**
- quinagolide - Norprolac (New drug) 28(6) 156-8
- hypertension (see also antihypertensives)**
- ACE inhibitors vs diuretics 27(4) 98-101
- beta blockers 30(1) 5-7
- - letter 30(3) 59-63

- management of uncomplicated hypertension 28(2) 34-7
- - letter 28(5) 113-5
- paracetamol and blood pressure (letter) 30(3) 59-63
- hypertension, pulmonary**
- treprostinil - Remodulin (New drug) 27(6) 159-65
- hyperthyroidism**
- thyroxine administration and pharmacokinetics 27(3) 75-6
- hypnotics**
- temazepam capsules and injecting drug users 27(3) 58-9
- - letter 27(5) 109-13
- hypoglycaemic drugs**
- exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7
- insulin therapy in diabetes 27(4) 93-6
- metformin in pregnancy and lactation 30(3) 68-9
- thiazolidinedione pharmacology 27(3) 67-70; 27(3) 70-4
- hypokalaemia**
- intravenous potassium chloride fatalities 28(1) 14-6
- - letters 28(4) 84-7
- hypomagnesaemia**
- abnormal laboratory results 30(4) 102-5
- - letter 30(6) 140-41
- hyponatraemia**
- drug-induced
- - letters 27(3) 55-7; 27(2) 28-33
- omeprazole 28(2) 48-9
- tramadol-induced 27(4) 97
- - letter 28(2) 29-33
- hypothyroidism**
- thyroxine administration and pharmacokinetics 27(3) 75-6
- - shelf-life of thyroxine (letter) 28(1) 5-7
- - - and refrigeration (letter) 29(2) 32-5
- hypovolaemia**
- pentastarch - Voluven (New drug) 30(4) 107-11

I

If current inhibitors

- ivabradine - Corolan - angina (New drug) 30(2) 50-55
- Ialex**
- see cephalixin 27(5) 131-3
- ibuprofen**
- and asthma 27(4) 87
- in childhood fever (letter) 27(3) 55-7
- iloprost**
- Ventavis - pulmonary hypertension (New drug) 27(3) 76-9
- imatinib**
- adult leukaemia 29(3) 76-9

immunisation - see vaccination

immunocytochemistry

- abnormal laboratory results 30(5) 128-9

immunophenotyping

- abnormal laboratory results 30(5) 128-9

immunosuppressants

- clinical and experimental pharmacology 29(4) 99-101; 29(4) 102-8
- everolimus - Certican (New drug) 28(3) 75-9
- in myasthenia gravis 30(6) 156-60

incretins

- exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7

Infanrix

- see vaccination, immunisation: specific vaccines - diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b 27(6) 159-65

infants

- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- overdoses of over-the-counter drugs in infantile colic 29(3) 83
- poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9

infection

- antibiotics for surgical prophylaxis 28(2) 38-40
- - dental notes 28(2) 41
- C-reactive protein - abnormal laboratory results 30(3) 74-6
- management of dental and oral pain 30(3) 77-9

infertility

- polycystic ovary syndrome 27(5) 129-31
- - letter 28(3) 55-8

inflammation

- C-reactive protein - abnormal laboratory results 30(3) 74-6
- management of dental and oral pain 30(3) 77-9

- monoclonal antibodies 29(5) 130-3

infliximab

- rheumatoid arthritis 27(2) 43-6
- tumour necrosis factor blockers in rheumatology 29(3) 67-70

influenza

- antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1
- vaccination
- - for healthy adults 30(2) 35-7
- - - letter 30(5) 116
- - - PBAC question 30(3) 83
- vaccine - Fluad (New brand) 27(2) 50-1

information services

- Adverse Medicine Events Line 27(2) 38
- internet and general practice 27(1) 16-8
- patient support organisations 27(1) 19-21

inhalation devices

- combination inhalers 28(2) 26-8

injections

- managing painful paediatric procedures 29(4) 94-6

- - letters 29(6) 149-50

INomax

- see nitric oxide 31(1) 24-7

Inspira

- see eplerenone 28(5) 130-1

- - letter 29(2) 32-5

insulin

- therapy and hypoglycaemic drugs in diabetes 27(4) 93-6

insulin detemir

- Levemir FlexPen - diabetes (New drug) 28(5) 130-1

insulin glargine

- diabetes - Lantus (New drug) 27(2) 50-1

- - letter 27(6) 138-41

insulin glulisine

- diabetes - Apidra SoloStar (New drug) 30(5) 133-5

insulin resistance

- in polycystic ovary syndrome 27(5) 129-31

- - letter 28(3) 55-8

- in schizophrenia 27(5) 118-9

Intal CFC-free

- see sodium cromoglycate 27(5) 131-3

interactions - see drug interactions

interferon

- peginterferon/ribavirin combination in hepatitis C 29(2) 36-9

interleukin-1 receptor antagonists

- anakinra - rheumatoid arthritis - Kineret (New drug) 27(6) 159-65

internet

- Australian Prescriber website user surveys 30(1) 16

- online information services and general practice 27(1) 16-8

interstitial nephritis

- with omeprazole (medicinal mishap) 30(3) 67

iobenguane

- MIBGen - adrenal tumour localisation (New drug) 27(5) 131-3

irinotecan

- New brand 28(3) 75-9

iron overload

- deferasirox - Exjade (New drug) 29(4) 112-5

iron sucrose

- Venofer - iron deficiency anaemia in haemodialysis 28(2) 49-51

- - letter 28(4) 84-7

isomaltulose

- sugar substitute - warning in fructose metabolism disorders (letter) 31(1) 3-4

isomerism

- chiral drugs - pharmacology and efficacy 27(2) 47-9

- - correction 28(3) 55-8

- - letter 27(5) 109-13

isosorbide mononitrate

- Arsorb (New brand) 27(1) 21-3

isotretinoin

- in acne 28(3) 59-61

ivabradine

- Corolan - angina (New drug) 30(2) 50-55

J

jaw diseases

- bisphosphonates and avascular necrosis (letter) 27(2) 28-33

- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7

jellyfish

- management of stings 30(5) 117-21

K

Karlor

- see cefaclor 27(5) 131-3

Kepivance

- see palifermin 28(6) 156-8

keratinocyte growth factor

- palifermin - oral mucositis prevention in chemotherapy - Kepivance (New drug) 28(6) 156-8

keratoses, actinic

- methyl-5-aminolevulinic acid - Metvix (New drug) 27(3) 76-9

ketotifen

- Zaditen - seasonal allergic conjunctivitis (New drug) 28(1) 19-23

- - correction 28(3) 75-9

kidney disease

- drug dosage adjustment 30(1) 17-20

- - letter 30(2) 32-4

- drug treatment of renal cell cancer 29(6) 151-3

- iron sucrose - iron deficiency anaemia in haemodialysis - Venofer (New drug) 28(2) 49-51

- - letter 28(4) 84-7

- lanthanum carbonate hydrate - hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5

- renal cell cancer

- - drug treatment 29(6) 151-3

- sevelamer - hyperphosphataemia in chronic renal disease - Renagel (New drug) 28(6) 156-8

- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71

- sunitinib - Sutent - renal cell cancer (New drug) 29(6) 167-71

kidney failure

- omeprazole and interstitial nephritis 30(3) 67

kidney function tests

- drug dosage adjustment in kidney disease 30(1) 17-20

- - letter 30(2) 32-4

kidney transplantation

- everolimus - Certican (New drug) 28(3) 75-9

Kineret

- see anakinra 27(6) 159-65

Kytril

- see granisetron 27(4) 101-5

L

laboratory results - see abnormal

laboratory results

labour

- pethidine in labour pain 27(2) 34-5

lactation

- antidepressants 30(5) 125-7

- antipsychotics 30(6) 162-3

- 'Drugs and breastfeeding' (book review) 27(6) 154

- - metronidazole (letter) 28(2) 29-33

- metformin and diabetes 30(3) 68-9

lamotrigine

- in bipolar disorders 30(3) 70-3

lanthanum carbonate hydrate

- Fosrenol - hyperphosphataemia in chronic renal failure (New drug) 29(2) 53-5

Lantus

- see insulin glargine 27(6) 138-41; 27(2) 50-1

lapatinib

- breast cancer - Tykerb (New drug) 30(5) 133-5

laronidase

- Aldurazyme - mucopolysaccharidosis I (New drug) 30(3) 79-82

laxatives

- bowel preparation 28(1) 16-7

legal issues

- Disputes and dilemmas in health law - book review 30(4) 105-6

- prescribing and the law (editorial) 27(5) 108-9

- - letters 28(2) 29-33

- - use of Latin (Letters) 28(2) 29-33

- publishing of drug evaluations (editorial) 29(5) 120

- - letter 30(2) 32-4

lercanidipine

- Zanidip (New strength) 27(2) 50-1

leukaemia

- alemtuzumab - MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71

- dasatinib - Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55

- treatment of adult leukaemia 29(3) 76-9

leuprorelin

- Eligard (New brand) 27(2) 50-1

Levemir FlexPen

- see insulin detemir 28(5) 130-1

levobupivacaine

- Chirocaine (New strength) 27(5) 131-3

Lexapro

- see escitalopram oxalate 27(2) 28-33

LHRH - see luteinising hormone releasing hormone**Li - see lithium****Lipidil**

- see fenofibrate 27(4) 101-5

lithium

- in bipolar disorders 30(3) 70-3

liver - see also hepatitis

- disodium gadoxetate - Primovist - liver

imaging (New drug) 29(3) 84-7

- liver function tests - hepatitis C 29(2) 36-9

Lucentis

- - see ranibizumab 30(3) 79-82

lumiracoxib

- Prexige - analgesia (New drug) 29(1) 25-7

- vascular effects of COX-2 selective inhibitors 27(6) 142-5

lung cancer

- angiogenesis inhibitors 29(1) 13-5

- erlotinib - Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5

- pemetrexed disodium - Alimta (New drug) 28(1) 19-23

lung diseases, chronic

- management 30(3) 64-7

- - letter - alpha-1-antitrypsin deficiency 30(6) 140-41

- patient support organisations 30(3) 79

lung function tests

- Pocket guide (book review) 29(3) 70

Lyrica

- see pregabalin 28(3) 75-9

lysosome storage diseases

- laronidase - mucopolysaccharidosis I - Aldurazyme (New drug) 30(3) 79-82

M

MabCampath

- see alemtuzumab 29(6) 167-71

macular degeneration

- anecortave - Retaane (New drug) 29(2) 53-5

- ranibizumab - Lucentis (New drug) 30(3) 79-82

magnesium

- abnormal laboratory results 30(4) 102-5

- - letter 30(6) 140-41

magnetic resonance angiography

- in neuroradiology 31(1) 18-20

magnetic resonance imaging

- disodium gadoxetate - Primovist - liver imaging (New drug) 29(3) 84-7

- gadobenate dimeglumine - MultiHance (New drug) 27(6) 159-65

Mantoux test

- BCG vaccine

- - letters 27(2) 28-33

mass media

- Media Doctor - website review 28(1) 13

Maxamox

- see amoxicillin 27(1) 21-3

Media Doctor

- website review 28(1) 13

medicinal mishap

- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7

- brand confusion with digoxin 29(6) 153

- cabergoline-induced valvulopathy 31(1) 21

- cross-reactivity of penicillins and

cephalosporins 30(1) 25-6

- dosing errors with infant drops 29(3) 83

- fenofibrate-warfarin interaction 29(6) 166

- hyponatraemia and omeprazole 28(2) 48-9

- ibuprofen and asthma 27(4) 87

- interstitial nephritis and omeprazole 30(3) 67

- neutropenia with quetiapine 31(1) 10-11

- serotonin syndrome and over-the-counter medicine 29(3) 71

- 'statins' and muscle symptoms 28(4) 102

- - letter 28(6) 136-9

- tramadol and hyponatraemia 27(4) 97

Medicines Australia (see also APMA)

- code of conduct breaches 30(6) 153-5;

29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(3) 60; 27(1) 6-7

- - vardenafil 30(6) 154

medroxyprogesterone and conjugated oestrogens

- Premia Low (New strength) 27(1) 21-3

MedSafety

- online learning system for medication error prevention (letter) 27(5) 109-13

memory disorders

- neurocognitive effects of chemotherapy 31(1) 22-4

Meniere's syndrome

- diagnosis and management of dizziness 28(4) 94-7

- patient support organisations 28(4) 107

mesalazine

- Pentasa, Salofalk (New formulations) 27(4) 101-5

mesothelioma

- pemetrexed disodium - Alimta (New drug) 28(1) 19-23

metformin

- in polycystic ovary syndrome 27(5) 129-31

- - letter 28(3) 55-8

- in pregnancy and lactation 30(3) 68-9

- thiazolidinediones 27(3) 70-4

methadone

- dextromethorphan and serotonin syndrome (letter) 29(6) 149-50

methyl-5-aminolevulinate

- Metvix - skin cancer (New drug) 27(3) 76-9

methyphenidate

- Concerta (New brand) 27(2) 50-1

metoprolol succinate

- Toprol-XL (New formulation) 27(3) 76-9

metoprolol tartrate

- Metrol (New brand) 27(1) 21-3

Metrol

- see Metoprolol tartrate 27(1) 21-3

metronidazole

- and breastfeeding (letter) 28(2) 29-33

Metvix

- see methyl-5-aminolevulinate 27(3) 76-9

MIBGen

- see iobenguane 27(5) 131-3

migraine

- and analgesic overuse 28(6) 143-5

- - letter 29(3) 59-62

milk, human

- 'Drugs and breastfeeding' (book review) 27(6) 154

- - metronidazole (letter) 28(2) 29-33

mini-mental state examination

- mental status testing in dementia 28(1) 11-3

mirtazapine

- Axit (New brand) 27(1) 21-3

monoclonal antibodies

- abciximab - non-malignant disease 29(5) 130-3

- adalimumab

- - Humira - rheumatoid arthritis (New drug) 27(4) 101-5

- - tumour necrosis factor blockers - rheumatoid arthritis 27(2) 43-6

- alemtuzumab - MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71

- basiliximab - non-malignant disease 29(5) 130-3

- bevacizumab - Avastin - colorectal cancer (New drug) 28(4) 104-6

- daclizumab - non-malignant disease 29(5) 130-3

- efalizumab - Raptiva - psoriasis (New drug) 28(1) 19-23

- infliximab

- - tumour necrosis factor blockers - rheumatoid arthritis 27(2) 43-6

- muromonab - non-malignant disease 29(5) 130-3

- natalizumab

- - multiple sclerosis - Tysabri (New drug) 30(4) 107-11

- - non-malignant disease 29(5) 130-3

- in non-malignant disease 29(5) 130-3

- ranibizumab - macular degeneration - Lucentis (New drug) 30(3) 79-82

- rituximab - non-malignant disease 29(5) 130-3

mouth

- drug and radiotherapy-induced xerostomia 29(4) 97-8
- - dental notes 29(4) 108
- - letters 30(1) 3-4

moxonidine

- Physiotsens - hypertension (New drug) 29(1) 25-7

mucopolysaccharidosis I

- laronidase - Aldurazyme (New drug) 30(3) 79-82

MultiHance

- see gadobenate dimeglumine 27(6) 159-65

multiple sclerosis

- magnetic resonance imaging in neuroradiology 31(1) 18-20
- natalizumab - Tysabri (New drug) 30(4) 107-11

muscle disorders

- and statins 28(4) 102
- - letter 28(6) 136-9

muscle symptoms

- with simvastatin (medicinal mishap) 28(4) 102

myasthenia gravis

- Australian Myasthenic Association in NSW 30(6) 160
- dental notes 30(6) 160
- patient's perspective 30(6) 161
- treatment 30(6) 156-60

mycophenolate mofetil

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

myeloma, multiple

- bortezomib - Velcade (New drug) 29(3) 84-7

myocardial infarction - see also coronary disease

- eplerenone - Inspra (New drug) 28(5) 130-1
- - letter 29(2) 32-5

N

natalizumab

- Tysabri - multiple sclerosis (New drug) 30(4) 107-11

National Medicines Policy

- Aboriginal people
- - letter 27(3) 55-7
- quality use of generic drugs (editorial) 27(4) 80-1
- - letters 28(2) 29-33; 27(6) 138-41

nausea

- aprepitant - Emend - cancer chemotherapy (New drug) 27(3) 76-9
- granisetron - Kytril (New drug) 27(4) 101-5

necrosis

- spider bites 29(6) 156-8

neonatal - see newborn

NeoRecormon

- see epoetin beta 29(4) 112-5

nephritis, interstitial

- omeprazole adverse effects 30(3) 67

neuralgia

- drug treatment of neuropathic pain 29(3) 72-5
- post-herpetic - pregabalin - Lyrica (New drug) 28(3) 75-9

neuralgia, trigeminal

- patient support organisation 29(3) 75

neuraminidase inhibitors

- antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1

neurokinin antagonists

- aprepitant - Emend - emetogenic cancer chemotherapy (New drug) 27(3) 76-9

neurology

- magnetic resonance imaging in neuroradiology 31(1) 18-20
- Therapeutic Guidelines - book reviews 30(4) 91

neuropathic pain

- drug treatment 29(3) 72-5
- - dental notes 29(3) 82
- pregabalin - Lyrica (New drug) 28(3) 75-9

neutropenia

- quetiapine (medicinal mishap) 31(1) 10-11

New Zealand

- direct-to-consumer advertising (editorial) 29(2) 30-2

newborn

- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9

Nexavar

- see sorafenib 29(6) 167-71

Nexium

- see esomeprazole 27(6) 159-65

nicotine

- varenicline - Champix (New drug) 31(1) 24-7

nicotine replacement therapy

- smoking cessation guidelines 28(3) 73-5
- - letter 28(6) 136-9

nitric oxide

- neonatal respiratory failure - INOmax (New drug) 31(1) 24-7

nitrofurantoin

- risks and benefits (letter) 27(4) 82-3

non-steroidal anti-inflammatory drugs - see anti-inflammatory drugs

Norprolac

- see quinagolide 28(6) 156-8

Noxafil

- see posaconazole 29(3) 84-7

NPS - see National Prescribing Service

NSAIDS - see anti-inflammatory drugs

number needed to treat

- interpreting risks and ratios in clinical trials 31(1) 12-6

Nupentin

- see gabapentin 27(5) 131-3

nurse prescribers

- competency (editorial) 30(3) 58-9
- prescribing (editorial) 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90

nutrition - see diet

Nyogel

- see timolol 28(3) 75-9

O

obesity

- diabetes and antipsychotics 27(5) 118-9
- management 29(2) 43-7

obstetrics

- carbetocin - prevention of uterine atony after caesarian section - Duratocin (New drug) 30(4) 107-11
- pethidine in labour pain 27(2) 34-5

oesophagitis - see gastro-oesophageal reflux

oestrogens

- medroxyprogesterone combination - Premia Low (New strength) 27(1) 21-3

off-label prescribing

- children (editorial)
- - letters 28(1) 5-7; 27(2) 28-33
- letter 27(4) 82-3

olanzapine

- in bipolar disorders 30(3) 70-3
 - in pregnancy and breastfeeding 30(6) 162-3
 - Zyprexa (New formulation) 27(4) 101-5
- ## older persons - see aged
- ## olmesartan medoxomil
- Olmetec - hypertension (New drug) 30(3) 79-82

Olmetec

- see olmesartan medoxomil 30(3) 79-82

omeprazole

- gastrointestinal haemorrhage (letter) 28(6) 136-9
- and hyponatraemia 28(2) 48-9
- and interstitial nephritis 30(3) 67

oncology - see cancer; antineoplastics

ophthalmic solutions

- correct use of eye drops 31(1) 16-17

opioids

- neuropathic pain 29(3) 72-5

oral contraceptives - see contraceptives

oral mucositis

- palifermin - Kepivance (New drug) 28(6) 156-8

Orencia

- see abatacept 30(6) 163-7

orlistat

- management of obesity 29(2) 43-7

Orphan Drug Scheme

- rifampicin and MRSA infections (letter) 29(1) 3-5

osteitis deformans - see Paget's disease of bone

osteoarthritis - see also arthritis

- glucosamine (PBAC question) 28(2) 48
- lumiracoxib - Prexige (New drug) 29(1) 25-7
- of the knee - glucosamine 27(3) 61-3
- - letter 27(5) 109-13

osteonecrosis

- bisphosphonates and avascular necrosis of the jaw (letter) 27(2) 28-33
- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7

osteoporosis

- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7
- calcium supplementation
- - letter 27(4) 82-3
- strontium ranelate - Protos (New drug) 28(6) 156-8
- teriparatide - Forteo (New drug) 27(1) 21-3
- - letter 27(5) 109-13

over-the-counter medicines

- aspirin, alcohol and gastric bleeding 28(1) 18-9
- - letter 28(4) 84-7
- cold remedy precipitating serotonin syndrome 29(3) 71
- - letter 29(6) 149-50
- overdoses of anticholinergic drugs in infantile colic 29(3) 83
- regulation of advertising 27(5) 124-7
- retail pharmacy promotions (letters) 27(2) 28-33

overactive bladder

- darifenacin hydrobromide - Enablex (New drug) 29(5) 138-43
- solifenacin succinate - Vesicare - (New drug) 29(5) 138-43
- tolterodine - Detrusitol (New drug) 28(2) 49-51

overdose

- psychostimulant poisoning 29(4) 109-11

overweight - see obesity

ovulation inducers - see fertility drugs

oximetry

- diagnostic tests
- - nail polish removal (letter) 27(2) 28-33

oxybutynin

- overactive bladder 29(1) 22-4

oxycodone

- OxyContin (New strength) 27(1) 21-3

OxyContin

- see oxycodone 27(1) 21-3

P

paclitaxel

- breast cancer (PBAC question) 30(1) 24-5

paediatrics - see children

pain

- management of dental and oral pain 30(3) 77-9
- managing painful paediatric procedures 29(4) 94-6; 29(4) 108
- - letters 29(6) 149-50
- neuropathic - drug treatment 29(3) 72-5
- - dental notes 29(3) 82
- perioperative analgesia 27(6) 152-4
- - letter 28(2) 29-33
- Pharmaceutical Benefits Scheme restrictions on analgesics for the aged (PBAC question) 27(6) 155
- - update 27(6) 155
- pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9

palifermin

- Kevance - oral mucositis prevention in chemotherapy (New drug) 28(6) 156-8

Palladone XL

- see hydromorphone 28(3) 75-9

palliative care

- pancreatic carcinoma 28(2) 42-4
- Therapeutic Guidelines - book review 29(3) 79

pancreatic carcinoma

- chemotherapy 28(2) 42-4

pandemics

- see disease outbreaks 30(2) 30-1

papillomavirus vaccine

- Cervarix (New drug) 30(5) 133-5
- Gardasil (New drug) 29(5) 138-43

paracetamol

- gastrointestinal bleeding and hypertension (letter) 30(3) 59-63
- hepatotoxicity and alcohol 27(1) 14-5
- and ibuprofen in childhood fever (letter) 27(3) 55-7
- letter 28(2) 29-33

parathyroid hormone

- osteoporosis - teriparatide - Forteo (New drug) 27(1) 21-3

paroxetine

- selective serotonin reuptake inhibitors and suicide risk in children (editorial) 28(5) 111-3
- - letter 29(2) 32-5

patents

- evergreening drug patents (editorial) 29(6) 148-9

pathology, diagnostic - see abnormal

laboratory results

patient compliance

- Aboriginal patients 28(5) 123-5

patient support organisations

- Alzheimer's Australia 28(3) 72
- Australian Hepatitis Council 29(2) 39
- Australian Lung Foundation 30(3) 79
- Australian Myasthenic Association in NSW 30(6) 160
- Continence Foundation of Australia 29(1) 24
- Diabetes Australia 27(4) 96-7
- Meniere's Support Group 28(4) 107
- Quitline (smoking cessation) 28(3) 73-5
- role in patient care 27(1) 19-21
- Trigeminal Neuralgia Association of Australia 29(3) 75

patient's perspective

- myasthenia gravis 30(6) 161

Paxam

- see clonazepam

PBAC - see Pharmaceutical Benefits

Advisory Committee

PBAC answers to questions

- influenza vaccination 30(3) 83
- specific drugs
- - adrenaline 28(4) 90
- - - auto-injectors - repeat prescriptions 28(4) 90
- - - shelf-life 29(2) 52-3
- - analgesics and the aged 27(6) 155
- - - update 28(1) 11-3
- - aprepitant as antiemetic in cancer chemotherapy 28(5) 119
- - glucosamine and osteoarthritis 28(2) 48
- - taxanes and breast cancer 30(1) 24-5
- - tramadol adverse effects 27(2) 26-7

PBS - see Pharmaceutical Benefits Scheme

peginterferon alfa-2a/ribavirin

combination

- hepatitis C 29(2) 36-9

peginterferon alfa-2b/ribavirin

combination

- hepatitis C 29(2) 36-9

pemetrexed disodium

- Alimta - lung cancer, mesothelioma (New drug) 28(1) 19-23

penicillin

- allergy
- - cephalosporin cross-reactivity 30(1) 25-6

Pentasa

- see mesalazine 27(4) 101-5

pentastarch

- Voluven - hypovolaemia (New drug) 30(4) 107-11

peptic ulcer

- management of gastrointestinal haemorrhage 28(3) 62-6
- - letter 28(6) 136-9
- proton pump inhibitors - long-term management 31(1) 5-7

peptides

- cyclic citrullinated antibodies in rheumatoid arthritis 29(6) 162-4

perflutren

- Definity - ultrasound contrast medium (New drug) 30(4) 107-11

perindopril

- patent evergreening (editorial) 29(6) 148-9

perindopril erbumine

- Coversyl (New strength) 27(2) 50-1

periodontitis

- adverse drug effects 29(6) 154-5
- and diabetes 27(2) 36-8
- management of dental and oral pain 30(3) 77-9

personal experiences of illness - see**patient's perspective****pertussis, diphtheria and tetanus vaccine**

- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b
 - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65

pethidine

- in labour pain 27(2) 34-5

Pharmaceutical Benefits Scheme

- drug price reforms (editorial) 30(6) 138-40
- expensive drugs (editorial) 29(6) 146-8
 - letter 30(3) 59-63
- expensive new drugs (editorial) 27(6) 136-7
 - letter 28(3) 55-8
- prescribing and the law (editorial) 27(5) 108-9
 - letters 28(2) 29-33; 28(2) 29-33
- transparency of information about new drugs (editorial) 28(4) 83-4
- US Free Trade Agreement (editorial) 27(3) 54-5
 - letter 27(5) 109-13
- withdrawal of drugs from the market
 - letters 27(2) 28-33

pharmaceutical industry - see drug industry**pharmaceutical promotion - see advertising****pharmacokinetics**

- chiral drugs 27(2) 47-9
 - correction 28(3) 55-8
 - letter 27(5) 109-13
- generic drugs 30(2) 41-3
 - letters 30(4) 88-90

pharmacology - clinical and experimental pharmacology

- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5
- Goodman & Gilman's 'The pharmacological basis of therapeutics' (book review) 29(1) 25
- immunosuppressants 29(4) 99-101; 29(4) 102-8
- thiazolidinediones 27(3) 67-70; 27(3) 70-4
 - letter 27(6) 138-41

phosphate binders

- lanthanum carbonate hydrate - hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5

Physiotens

- see moxonidine 29(1) 25-7

pilocarpine

- management of xerostomia 29(4) 97-8
 - letters 30(1) 3-4

pimecrolimus

- atopic dermatitis - Elidel (New drug)
 - letter 27(2) 28-33

pioglitazone

- pharmacology 27(3) 67-70; 27(3) 70-4
 - letter 27(6) 138-41

plasma volume expanders

- pentastarch - Voluven (New drug) 30(4) 107-11

platelet antagonists

- coronary stents 30(4) 92-96

Pocket guide to lung function tests

- book review 29(3) 70

poisoning

- management of injuries by sea creatures 30(5) 117-21
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8

poliomyelitis

- vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65

polycystic ovary syndrome

- drug treatment 27(5) 129-31
 - letter 28(3) 55-8

polypharmacy

- editorial 31(1) 2-3

polypill

- prevention of cardiovascular disease (editorial) 28(4) 82-3

poractant alfa

- Curosurf - neonatal respiratory distress syndrome (New drug) 28(3) 75-9

posaconazole

- Noxafil - fungal infections (New drug) 29(3) 84-7

post-menopausal symptoms - see menopause**potassium chloride, intravenous**

- adverse effects 28(1) 14-6
 - letter 28(4) 84-7

pre-eclampsia

- biochemical tests for abnormalities in pregnancy (letter) 29(4) 91-3

prednisone

- in myasthenia gravis 30(6) 156-60

pregabalin

- Lyrica - epilepsy, neuropathic pain (New drug) 28(3) 75-9

pregnancy - see also birth defects

- abnormal laboratory results - biochemical tests 28(4) 98-101
 - letters 29(1) 3-5; 28(6) 136-9
- antidepressants 30(5) 125-7
- antipsychotics 30(6) 162-3
- biochemical tests for abnormalities 29(2) 48-52
 - letter 29(4) 91-3
- metformin and diabetes 30(3) 68-9

premenstrual dysphoric disorder

- treatment with antidepressants 28(4) 91-3

Premia Low

- see oestrogens, conjugated and medroxyprogesterone 27(1) 21-3

prescribing patterns, costs, etc. - see drug utilisation; cost of drugs**preventative medicine**

- the polypill and cardiovascular disease (editorial) 28(4) 82-3

Prexige

- see lumiracoxib 29(1) 25-7

Prezista

- see darunavir 30(3) 79-82

price of drugs - see cost of drugs**primary health care**

- 'Aboriginal primary health care' (book review) 27(1) 9
- 'CARPA Standard Treatment Manual' (book review) 27(1) 8

Primovist

- see disodium gadoxetate 29(3) 84-7

prostacyclin

- iloprost - Ventavis - pulmonary hypertension (New drug) 27(3) 76-9

prostacyclin analogues

- treprostinil - pulmonary arterial hypertension - Remodulin (New drug) 27(6) 159-65

protein C

- Ceprotin - congenital protein C deficiency (New drug) 30(2) 50-55

proton pump inhibitors

- hyponatraemia with omeprazole (medicinal mishap) 28(2) 48-9
- long-term management 31(1) 5-7
- omeprazole and interstitial nephritis 30(3) 67

Protos

- see strontium ranelate 28(6) 156-8

psoriasis

- alefacept - Amevive (New drug) 27(4) 101-5
- efalizumab - Raptiva (New drug) 28(1) 19-23
- tazarotene - Zorac (New drug) 29(3) 84-7

psychotic disorders

- long-term community management 30(2) 44-6

psychotropic drugs

- in childhood and adolescence 28(5) 116-8
- and dentistry 30(4) 98-101

- Therapeutic Guidelines: Psychotropic (book review) 27(2) 50
- puberty**
- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- public health**
- funding of influenza vaccination for healthy adults 30(2) 35-7
- letter 30(5) 116
- PubMed**
- online information services and general practice 27(1) 16-8
- pulmonary disease, chronic obstructive**
- COPD in primary care (book review) 27(1) 13
- management 30(3) 64-7
- letter - alpha-1-antitrypsin deficiency 30(6) 140-41
- patient support organisations 30(3) 79
- pulmonary hypertension**
- iloprost - Ventavis (New drug) 27(3) 76-9
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- treprostinil - Remodulin (New drug) 27(6) 159-65
- pulmonary rehabilitation**
- chronic obstructive pulmonary disease 30(3) 64-7
- pyridostigmine**
- in myasthenia gravis 30(6) 156-60

Q

- QTc interval - see arrhythmia**
- quality use of medicines - see drug information; drug therapy; drug utilisation**
- quetiapine**
- neutropenia (medicinal mishap) 31(1) 10-11
- quinagolide**
- Norprolac - hyperprolactinaemia (New drug) 28(6) 156-8

R

- rabies vaccine**
- Rabipur (New drug) 29(1) 25-7
- Rabipur**
- see rabies vaccine 29(1) 25-7
- RADAR (Rational Assessment of Drugs and Research)**
- ezetimibe 27(5) 128
- risperidone in behavioural disturbances in dementia 28(3) 71
- radiography**
- 'Pocket guide to chest X-rays' (book review) 27(6) 158
- radiology**
- bowel preparation 28(1) 16-7

- radiotherapy**
- salivary glands and xerostomia 29(4) 97-8
- dental notes 29(4) 108
- letters 30(1) 3-4
- ranibizumab**
- Lucentis - macular degeneration (New drug) 30(3) 79-82
- Raptiva**
- see efalizumab 28(1) 19-23
- rasburicase rys**
- Fasturtec (New formulation) 27(6) 159-65
- reference pricing**
- drug price reforms (editorial) 30(6) 138-40
- Reminyl**
- see galantamine 27(4) 101-5
- Remodulin**
- see treprostinil 27(6) 159-65
- Renagel**
- see sevelamer 28(6) 156-8
- renal - see kidney**
- Replagal**
- see agalsidase alfa 27(5) 131-3
- Repreve**
- see ropinirole 28(1) 19-23
- respiration disorders**
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- Therapeutic Guidelines - book review 28(5) 129
- respiratory distress syndrome, neonatal**
- poractant alfa - Curosurf (New drug) 28(3) 75-9
- restless legs syndrome**
- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21
- ropinirole - Repreve (New drugs) 28(1) 19-23
- Retaane**
- see anecortave 29(2) 53-5
- retinal disease**
- macular degeneration - anecortave - Retaane (New drug) 29(2) 53-5
- retinoids**
- tazarotene - Zorac - psoriasis, acne (New drug) 29(3) 84-7
- Reyataz**
- see atazanavir - HIV infection 27(6) 159-65
- rheumatoid arthritis**
- abatacept - Orencia (New drug) 30(6) 163-7
- abnormal laboratory results - antibodies to cyclic citrullinated peptides 29(6) 162-4
- tumour necrosis factor inhibitors 27(2) 43-6
- rheumatoid factor**
- abnormal laboratory results - rheumatoid arthritis 29(6) 162-4
- rheumatology - see also arthritis; anti-inflammatory drugs**
- NSAIDs and cardiovascular disease (editorial) 29(4) 90-1

- Therapeutic Guidelines - book review 29(5) 124
- tumour necrosis factor inhibitors 29(3) 67-70; 27(2) 43-6
- letter 28(1) 5-7
- ribavirin**
- peginterferon/ribavirin combination in hepatitis C 29(2) 36-9
- rifampicin**
- MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5
- risk**
- 'Health care and notions of risk' (book review) 27(6) 159
- interpreting risks and ratios in clinical trials 31(1) 12-6
- pharmacotherapy for risk factors 30(2) 47-50
- letter 30(4) 88-90
- Risperdal**
- see risperidone 28(3) 71
- Risperdal Quicklet**
- see risperidone 27(4) 101-5
- risperidone**
- in behavioural disturbances in dementia (RADAR comment) 28(3) 71
- Risperdal Quicklet (New formulation) 27(4) 101-5
- rofecoxib**
- vascular effects of COX-2 selective inhibitors 27(6) 142-5
- letter 28(2) 29-33
- ropinirole**
- Repreve - restless legs syndrome (New drug) 28(1) 19-23
- rosiglitazone**
- pharmacology 27(3) 67-70; 27(3) 70-4
- letter 27(6) 138-41
- rosuvastatin**
- Crestor - hypercholesterolaemia (New drug) 29(6) 167-71
- Rotarix**
- see rotavirus vaccine 29(4) 112-5
- RotaTeq**
- see rotavirus vaccine 29(4) 112-5
- rotavirus vaccine**
- Rotarix (New drug) 29(4) 112-5
- RotaTeq (New drug) 29(4) 112-5

S

- salivary glands**
- drug- and radiotherapy-induced xerostomia 29(4) 97-8
- dental notes 29(4) 108
- letters 30(1) 3-4
- salmeterol**
- combination inhalers in asthma 28(2) 26-8
- safety concerns (editorial) 29(5) 118-9
- Salofalk**
- see mesalazine 27(4) 101-5

schizophrenia

- antipsychotic drugs and risk of diabetes 27(5) 118-9
- costs and benefits of atypical versus typical antipsychotics 27(6) 146-9; 27(6) 149-51
- long-term community management 30(2) 44-6
- ziprasidone - Zeldox (New drug) 30(2) 50-55
- - letter 30(3) 59-63

Sebivo

- see telbivudine 30(6) 163-7

sedatives

- psychotropic drugs and dentistry 30(4) 98-101

Sensipar

- see cinacalcet 28(3) 75-9

Septanest

- see articaine 28(1) 19-23

serotonin antagonists

- granisetron - nausea and vomiting - Kytril (New drug) 27(4) 101-5

serotonin reuptake inhibitors - see also antidepressant drugs

- antidepressants and suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5
- escitalopram oxalate - Lexapro (New drug)

- - letter 27(2) 28-33

- pregnancy and breastfeeding 30(5) 125-7

serotonin syndrome

- over-the-counter dextromethorphan 29(3) 71
- - letter 29(6) 149-50
- tramadol adverse effects (editorial) 27(2) 26-7

sevelamer

- Renigel - hyperphosphataemia in chronic renal disease (New drug) 28(6) 156-8

sexual abuse

- diagnosis and management of vulvovaginitis in childhood 28(4) 88-90

sexually transmitted infections

- abnormal laboratory results 30(1) 8-13

shingles

- varicella vaccine - frequently asked questions 28(1) 2-5
- - letters 28(5) 113-5; 28(3) 55-8
- zoster virus vaccine - Zostavax (New drug) 31(1) 24-7

sialogogues

- management of xerostomia 29(4) 97-8
- - letters 30(1) 3-4

sibutramine

- management of obesity 29(2) 43-7

simvastatin

- and muscle symptoms 28(4) 102
- - letter 28(6) 136-9

sirolimus

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

skin cancer

- methyl-5-aminolevulinatate - Metvix (New drug) 27(3) 76-9

smoking cessation

- guidelines 28(3) 73-5
- - letter 28(6) 136-9
- varenicline - Champix (New drug) 31(1) 24-7

snake bites

- management 29(5) 125-9

sodium

- drug-induced hyponatraemia
- - letters 27(3) 55-7; 27(2) 28-33

sodium cromoglycate

- Intal CFC-free (New formulation) 27(5) 131-3

sodium valproate

- see valproic acid 30(3) 70-3

Solian

- see amisulpride 27(3) 76-9

solifenacin succinate

- Vesicare - overactive bladder (New drug) 29(5) 138-43

sorafenib

- Nexavar - renal cell cancer (New drug) 29(6) 167-71
- renal cell cancer 29(6) 151-3

spider bites

- management 29(6) 156-8

spironolactone

- polycystic ovary syndrome 27(5) 129-31

sport

- anti-doping code 27(4) 84-7

Sprycel

- see dasatinib 30(2) 50-55

St John's wort

- in mild depression 28(1) 8-10

staphylococcal infections

- community-acquired methicillin-resistant infection 28(6) 155
- - letter 29(3) 59-62
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5

starter packs

- adverse effects 30(1) 14-16

statins - see antilipidaemic drugs

statistics

- book review - 'Statistics with common sense' 27(3) 66
- interpreting risks and ratios in clinical trials 31(1) 12-6

stem cell transplantation

- adult leukaemia 29(3) 76-9

steroids - see corticosteroids

stingrays

- management of stings 30(5) 117-21

Strattera

- see atomoxetine 27(4) 101-5

stress testing

- diabetes - exercise 30(5) 130-3

stroke - see cerebrovascular disorders

strontium ranelate

- Protos - postmenopausal osteoporosis (New drug) 28(6) 156-8

suicide

- risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5

sulfonamides

- allergy and cross-reactivity 31(1) 8-10

sulfonyleureas

- thiazolidinediones 27(3) 70-4

sunitinib

- renal cell cancer 29(6) 151-3
- Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71

surgery

- antibiotics for surgical prophylaxis 28(2) 38-40
- - dental notes 28(2) 41
- - letters 28(5) 113-5; 28(3) 55-8
- blood transfusion guidelines 28(2) 45-7
- perioperative analgesia 27(6) 152-4
- - letter 28(2) 29-33

Sutent

- see sunitinib 29(6) 167-71

syphilis

- abnormal laboratory results 30(1) 8-13

T

tacrolimus

- pharmacology of immunosuppressants 29(4) 99-101

Tarceva

- see erlotinib 29(2) 53-5

taxanes

- breast cancer (PBAC question) 30(1) 24-5

tazarotene

- Zorac - psoriasis, acne (New drug) 29(3) 84-7

telbivudine

- chronic hepatitis B - Sebivo (New drug) 30(6) 163-7

Telzir

- see fosamprenavir 28(1) 19-23

temazepam

- capsules and injecting drug users 27(3) 58-9
- - letter 27(5) 109-13

teratogens - see birth defects

teriparatide

- osteoporosis - Forteo (New drug) 27(1) 21-3
- - letter 27(5) 109-13

tetanus vaccine

- management of animal and human bites 29(1) 6-8

tetanus, diphtheria and pertussis vaccine

- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b
- Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65

thalassaemia

- deferasirox - Exjade - chelating agent (New drug) 29(4) 112-5

thalidomide

- angiogenesis inhibitors in cancer 29(1) 9-12
- tumour necrosis factor blockers in rheumatoid arthritis (letter) 28(1) 5-7

Therapeutic Goods Administration

- adverse reaction reporting systems 28(6) 140-2
- drug evaluation and approval processes 27(6) 156-8
- regulation of advertising in Australia 27(5) 124-7
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5

Therapeutic Guidelines

- book reviews
- - Antibiotic 30(3) 73
- - Dermatology 28(2) 44
- - Endocrinology 28(3) 58
- - Gastrointestinal 30(2) 46
- - Neurology 30(4) 91
- - Oral and Dental 30(4) 106
- - Palliative care 29(3) 79
- - Psychotropic 27(2) 50
- - Respiratory 28(5) 129
- - Rheumatology 29(5) 124
- PDA review - Mini TG (personal digital assistant version) 29(1) 21

therapeutic guidelines

- turning knowledge into action (editorial) 30(5) 114-5

thiazolidinediones

- pharmacology 27(3) 67-70; 27(3) 70-4
- - letter 27(6) 138-41

thromboembolism

- antiplatelet therapy after coronary stents 30(4) 92-96
- diagnosis of recurrent deep venous thrombosis 30(2) 38-40
- vascular effects of COX-2 selective inhibitors 27(6) 142-5
- - letters 28(2) 29-33
- warfarin risks and benefits 27(4) 88-92
- - cataract surgery (letter) 27(6) 138-41

thrombolytic drugs - see fibrinolytic

drugs; anticoagulants

thyroid function tests

- abnormal laboratory results in pregnancy 28(4) 98-101
- - letter 29(1) 3-5

thyroxine

- administration and pharmacokinetics 27(3) 75-6
- shelf-life and refrigeration (letters) 29(2) 32-5; 28(1) 5-7

tigecycline

- Tygacil - complicated infections (New drug) 29(5) 138-43

timolol

- new formulation - Timoptol-XE 28(3) 75-9

tinnitus

- Ginkgo biloba (editorial) 29(5) 120
- - letter 30(2) 32-4

tipranavir

- Aptivus - HIV infection (New drug) 30(4) 107-11

tolterodine

- Detrusitol - overactive bladder (New drug) 28(2) 49-51
- overactive bladder 29(1) 22-4
- - letter 29(4) 91-3

tooth - see dental, dentistry

top 10 drugs

- statistics 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37

Toprol-XL

- see metoprolol succinate 27(3) 76-9

toxicity

- Donnalix Infant Drops (medicinal mishap) 29(3) 83

tramadol

- adverse effects (editorial) 27(2) 26-7
- and hyponatraemia 27(4) 97
- - letter 28(2) 29-33
- Tramal oral drops (New formulation) 28(6) 156-8

Tramal

- see tramadol 28(6) 156-8

trandolapril

- Gopten (New formulation) 27(6) 159-65

transient ischaemic attacks

- early management of acute stroke 27(5) 120-3

transparency of information about new drugs - see drug evaluation, drug regulation

transplantation - see also specific organs

- everolimus - Certican (New drug) 28(3) 75-9
- immunosuppressants 29(4) 102-8

travel

- overseas travel and medicines 29(3) 80-2

treprostinil

- Remodulin - pulmonary arterial hypertension (New drug) 27(6) 159-65

tricyclic antidepressants - see

antidepressant drugs

trigeminal neuralgia

- patient support organisation 29(3) 75

tuberculosis

- BCG vaccination
- - letters 27(2) 28-33

tumour necrosis factor

- monoclonal antibodies 29(5) 130-3

tumour necrosis factor blockers

- rheumatoid arthritis 29(3) 67-70; 27(2) 43-6
- - letter 28(1) 5-7

tumour necrosis factor inhibitors - see

tumour necrosis factor blockers

Tygacil

- see tigecycline 29(5) 138-43

Tykerb

- see lapatinib 30(5) 133-5

tyrosine kinase inhibitors

- dasatinib - Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-55
- lapatinib - breast cancer - Tykerb (New drug) 30(5) 133-5
- renal cell cancer 29(6) 151-3
- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71
- sunitinib - Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71

Tysabri

- see natalizumab 30(4) 107-11

U

ulcers

- foot infections in diabetes 30(1) 21-4

ultrasound

- deep venous thrombosis 30(2) 38-40
- echocardiography 29(5) 134-8
- - letter 30(1) 3-4
- perflutren - contrast medium - Definity (New drug) 30(4) 107-11

United States

- US Free Trade Agreement and pharmaceuticals (editorial) 27(3) 54-5
- - letter 27(5) 109-13

uric acid

- management of gout 27(1) 10-3

urinary incontinence

- anticholinergic drugs 29(1) 22-4
- - letter 29(4) 91-3
- tolterodine - Detrusitol (New drug) 28(2) 49-51

V

vaccination, immunisation - see also injections

- cholera - Dukoral (New drug) 27(6) 159-65
- diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b
- - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65
- human papillomavirus
- - Cervarix (New drug) 30(5) 133-5
- - Gardasil (New drug) 29(5) 138-43
- influenza vaccination for healthy adults 30(2) 35-7
- - letter 30(5) 116
- - PBAC question 30(3) 83

- managing painful paediatric procedures 29(4) 94-6
- rabies - Rabipur (New drug) 29(1) 25-7
- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5
- specific vaccines - varicella vaccine 28(1) 2-5
- - letters 28(5) 113-5; 28(3) 55-8
- tetanus vaccine in management of animal and human bites 29(1) 6-8
- tuberculosis - BCG vaccine
- - letters 27(2) 28-33
- varicella
- - vaccination (letter) 30(5) 116
- zoster virus vaccine - Zostavax (New drug) 31(1) 24-7
- Valette**
- see dienogest/ethinyloestradiol 30(2) 50-55
- valproic acid**
- in bipolar disorders 30(3) 70-3
- Vaniqa**
- see eflornithine hydrochloride 29(3) 84-7
- vardenafil**
- advertising - Medicines Australia code of conduct breaches 30(6) 154
- varenicline**
- Champix - smoking cessation (New drug) 31(1) 24-7
- varicella vaccine**
- frequently asked questions 28(1) 2-5
- - letters 28(5) 113-5; 28(3) 55-8
- vaccination (letter) 30(5) 116
- varices**
- management of gastrointestinal haemorrhage 28(3) 62-6
- vascular endothelial growth factor**
- angiogenesis inhibitors in cancer 29(1) 9-12
- vasoconstrictors**
- interactions with psychotropic drugs and dentistry 30(4) 98-101
- vasodilators**
- iloprost - Ventavis - pulmonary hypertension (New drug) 27(3) 76-9
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- Velcade**
- see bortezomib 29(3) 84-7
- Venofer**
- see iron sucrose 28(2) 49-51
- venomous fish**
- management of puncture injuries 30(5) 117-21
- Ventavis**
- see iloprost 27(3) 76-9
- vertigo**
- diagnosis and management 28(4) 94-7
- - dental treatment (letter) 28(6) 136-9

Vesicare

- see solifenacin succinate 29(5) 138-43

vestibular disorders

- diagnosis and management of dizziness 28(4) 94-7

vision disorders

- xanthopsia and digoxin dosages 29(6) 153

Voluven

- see pentastarch 30(4) 107-11

vomiting

- aprepitant - Emend - cancer chemotherapy (New drug) 27(3) 76-9
- granisetron - Kytril (New drug) 27(4) 101-5

vulvovaginitis

- butoconazole nitrate - Gynazole - candidal vulvovaginitis (New drug) 29(5) 138-43
- diagnosis and management in childhood 28(4) 88-90

W

wall chart

- anaphylaxis 30(5) 115

warfarin

- bioequivalence of Marevan and Coumadin (letters) 30(2) 32-4
- dental extractions (letter) 27(1) 3
- dental patients
- - letters 27(1) 3
- interactions with fenofibrate 29(6) 166
- - letter 30(2) 32-4
- risks and benefits 27(4) 88-92
- - cataract surgery (letter) 27(6) 138-41

wound infections

- antibiotics for surgical prophylaxis 28(2) 38-40
- - letters 28(5) 113-5; 28(3) 55-8
- management of animal and human bites 29(1) 6-8
- - letters 29(3) 59-62

wounds

- managing painful paediatric procedures 29(4) 94-6
- - letters 29(6) 149-50

X

X-rays, chest

- book review 27(6) 158

xanthopsia

- digoxin dosages 29(6) 153

xerostomia

- drug- and radiotherapy-induced 29(4) 97-8
- - dental notes 29(4) 97-8
- - letters 30(1) 3-4
- psychotropic drugs and dentistry 30(4) 98-101

Y

Z

Zaditen

- see ketotifen 28(1) 19-23

Zanidip

- see lercanidipine 27(2) 50-1

Zeldox

- see ziprasidone 30(2) 50-55
- see ziprasidone (letter) 30(3) 59-63

ziprasidone

- Zeldox - schizophrenia and bipolar I disorder (New drug) 30(2) 50-55
- - letter 30(3) 59-63

Zithromax

- Zithromax IV - see azithromycin 27(2) 50-1

Zorac

- see tazarotene 29(3) 84-7

Zostavax

- see zoster virus vaccine 31(1) 24-7

zoster virus vaccine

- Zostavax (New drug) 31(1) 24-7

Zyprexa

- see olanzapine 27(4) 101-5

Author Index

- Abbott PV 30(3) 77-9
Abramson M 30(3) 64-7
Adams J 29(1) 2-3
Adsett M 31(1) 21
Al-Sohaily S 31(1) 5-7
Aldrich R 27(1) 9
Allinson YM 28(1) 14-6
Ames D 29(3) 59-62
Anderson EA 30(1) 25-6
Annetts P 30(3) 83
Arnold T 31(1) 3-4
Aslani P 30(5) 122-4
Attia J 28(6) 134-5; 27(3) 66
Backhouse P 30(4) 96-7
Baird A 30(6) 143-6
Baker S 27(3) 55-7
Balassa J 29(6) 153
Barbehenn E 28(2) 29-33
Barnes D 29(6) 159-61
Bateman GA 31(1) 18-20
Batey R 29(2) 36-9
Baume M 27(5) 109-13
Beggs S 27(3) 55-7
Bellchambers H 30(1) 2-3
Bereznicki L 28(4) 84-7
Bochner F 27(2) 47-9
Borosak M 27(4) 88-92
Bowden SC 28(1) 11-3
Bowen K 30(1) 21-4
Bownas T 29(2) 32-5
Boyd B 31(1) 3-4
Boyle C 27(6) 155
Brand P 28(4) 84-7
Brennan J 28(2) 48
Brodaty H 29(3) 59-62
Broom J 29(1) 6-8
Buchan H 30(5) 114-5
Buckley N 29(4) 109-11
Buckley P 28(2) 44
Burrows GD 30(4) 86-8
Byrne GJ 28(3) 67-70
Cai FZJ 29(4) 90-1
Cameron C 29(3) 71
Cameron PD 28(4) 84-7
Campbell TJ 28(6) 150-4
Cannon PD 27(1) 3
Canny L 30(3) 59-63
Carapetis JR 28(1) 2-5
Carbonara S 31(1) 3-4
Carr V 27(6) 149-51
Carter A 30(4) 102-5
Carter GD 27(2) 28-33
Cartwright K 30(5) 128-9
Casey J 30(4) 91
Castellaro P 28(2) 29-33
Cateron ID 29(2) 43-7
Cheng A 29(1) 3-5
Chisholm DJ 27(3) 67-70
Choo C 31(1) 10-11
Choo S 28(6) 136-9; 27(4) 88-92
Clarke S 29(1) 9-12
Cleland LG 29(4) 90-1
Cocks T 27(6) 155
Comerford JA 27(4) 82-3
Commens C 30(6) 140-41; 29(4) 91-3
Cramer J 27(3) 55-7
Cranswick N 29(3) 83; 27(3) 55-7
Crawford G 29(3) 79
Dallimore K 29(2) 52-3
Darby I 29(6) 154-5
Davies CA 27(5) 124-7
Day RO 30(3) 59-63; 30(2) 32-4; 29(6) 146-8; 27(6) 142-5; 27(1) 14-5
Day S 27(1) 16-8
Dharmar VT 27(1) 3
di Paola I 28(3) 55-8
Dodd P 27(6) 152-4
Donovan J 27(6) 159
Dooley M 28(6) 136-9
Douglas R 29(6) 149-50
Dowden JS 30(6) 154; 30(4) 91; 29(5) 120; 29(1) 25; 28(5) 120-2; 27(3) 54-5
Dubury C 28(4) 84-7
Dugdale P 30(2) 35-7
Duggan A 31(1) 5-7
Dwyer S 30(3) 73
Editorial Executive Committee 28(4) 83-4
Elsik M 30(1) 5-7; 29(4) 93
Ewald B 28(5) 113-5
Farah CS 30(4) 106
Faull R 30(1) 17-20
Faunce T 30(6) 138-40
Ferguson J 27(2) 39-42
Ferrari V 27(2) 28-33
Fischer G 28(4) 88-90
Foster D 27(2) 47-9
Fraser R 28(3) 62-6
French J 30(3) 59-63
Fricker PA 27(4) 84-7
Gaetani L 29(5) 121
Gallego G 30(3) 59-63
Gazarian M 28(1) 5-7
Ghiculescu RA 29(6) 166
Gibbs H 30(2) 38-40
Gillman K 29(4) 91-3; 28(2) 29-33
Glasgow N 30(3) 64-7
Goldman GS 30(5) 116
Goldney RD 29(2) 32-5
Goldstein D 28(2) 42-4
Goss AN 30(4) 96-7; 30(1) 3-4; 28(3) 55-8; 27(2) 28-33
Goucke R 27(4) 82-3
Gould-Hurst P 28(2) 29-33
Grabau B 28(3) 55-8
Graham GG 30(3) 59-63; 30(2) 32-4; 27(6) 142-5; 27(1) 14-5
Grant P 28(4) 84-7
Greaves R 28(5) 126-9
Greenberg P 31(1) 10-11
Greenfield JR 27(3) 67-70
Greenway A 27(3) 64-6
Grubb D 27(6) 138-41; 27(5) 109-13; 27(2) 28-33
Gullotta J 30(4) 88-90
Hague WM 30(3) 68-9
Hall R 28(5) 122
Harvey K 30(2) 32-4; 27(3) 63
Hassali A 27(4) 80-1
Haw C 29(3) 59-62
Haworth D 27(4) 82-3
Hayhow BD 29(5) 122-4
Hazell P 28(5) 116-8
Headrick S 31(1) 21
Heffer R 30(1) 3-4
Hegarty K 28(1) 8-10
Helme RD 29(3) 72-5
Hemming M 28(1) 13
Herriot P 29(5) 121
Hill C 29(3) 67-70
Hill S 28(2) 34-7
Hilmer SN 31(1) 2-3; 29(3) 58-9
Hirsch R 27(2) 36-8
Ho J 30(6) 147-9
Hobbs M 27(6) 138-41
Hodson TJP 27(6) 138-41
Honson K 29(3) 59-62
Hope J 30(2) 44-6
Hourigan L 29(5) 134-8
Howell C 30(4) 105-6; 28(5) 129
Hughes R 27(6) 155
Hunt J 29(6) 149-50
Hunter R 27(4) 97; 27(2) 28-33
Iannuzzi A 30(2) 46-46
Isbister GK 30(5) 117-21; 29(6) 156-8; 29(5) 125-9
Isbister JP 28(2) 45-7
Jackson SL 29(5) 121
James H 29(3) 59-62
James MJ 29(4) 90-1
Jenkins C 29(3) 63-6
Jenkins N 27(2) 28-33
Jersmann H 28(6) 136-9
Jerums G 27(3) 70-4
Johnson D 30(2) 32-4
Jones G 30(2) 32-4
Joyner B 28(3) 58; 27(5) 129-31
Jureidini JN 28(5) 110-1
Kaiko E 27(6) 155
Katelaris C 31(1) 8-10; 30(1) 25-6
Kault D 30(4) 88-90
Kaye K 29(6) 146-8; 27(2) 26-7
Keks NA 30(2) 44-6; 27(6) 146-9
Kelly M 28(1) 5-7
Kelly MD 28(6) 146-9
Kennedy D 30(6) 162-3
Kennedy MA 30(6) 140-41
Kerr P 28(4) 84-7
Kerridge I 29(3) 76-9
Khan SA 29(3) 59-62

Kilpatrick CJ 27(5) 114-7
 Komesaroff PA 30(6) 150-3
 Kong D 27(4) 80-1
 Kopp C 29(3) 59-62
 Krum H 30(1) 5-7; 29(2) 32-5
 Kubler P 29(6) 148-9; 29(5) 124;
 28(2) 29-33
 Kuteesa W 29(1) 22-4
 Lake P 29(3) 59-62
 Lampe L 28(4) 91-3
 Landau J 31(1) 10-11
 Landau PB 27(5) 120-3
 Lander C 31(1) 21
 Languth D 29(6) 162-4
 Larkin C 28(5) 123-5
 Latham M 30(6) 161
 Lee L 30(1) 17-20
 Lees LA 28(2) 29-33
 Lewis T 30(6) 140-41
 Lexchin J 27(1) 2-3
 Litt J 28(3) 73-5
 Lloyd-Jones M 27(5) 109-13
 Lofgren H 30(6) 138-40
 Lowe MP 29(5) 122-4
 Lu CY 29(6) 146-8
 Lu K 31(1) 10-11
 Lu TYT 29(3) 67-70
 MacIsaac RJ 27(3) 70-4
 Mackay K 28(6) 140-2
 Mackintosh J 28(2) 48-9
 Mainwaring P 29(1) 13-5
 Mangin D 29(2) 30-2
 Mansfield PR 28(2) 29-33
 Marley J 28(4) 101
 Mathew T 30(2) 32-4
 McCann A 30(4) 92-96
 McColl G 27(3) 61-3; 27(2) 43-6
 McCormack D 29(4) 109-11
 McCullagh V 28(1) 5-7
 McCullough M 30(6) 146; 30(6)
 153; 30(6) 160; 30(2) 37-37;
 30(2) 43-43; 30(1) 13; 29(4)
 108; 29(4) 108; 29(3) 82;
 29(2) 52; 28(6) 142; 28(6)
 149
 McDonald C 30(3) 64-7
 McErlane S 27(3) 55-7
 McGill N 27(1) 10-3
 McGuire TM 30(1) 14-16; 28(4)
 102
 McLachlan A 30(2) 41-3; 29(2)
 40-2
 McLernon N 28(2) 29-33
 McMillan M 30(1) 2-3
 McNulty A 27(2) 28-33
 McPhee J 28(1) 5-7
 Meade CE 28(1) 11-3
 Milne RW 30(2) 41-3
 Mitchell PB 30(3) 70-3
 Monagle P 27(3) 64-6
 Montgomery B 28(4) 93
 Moore KH 29(1) 22-4
 Moro P 30(3) 59-63
 Morton A 28(6) 136-9; 28(2)
 48-9
 Moses GM 28(4) 102
 Moulds RFW 27(6) 136-7; 27(5)
 117
 Munckhof W 28(2) 38-40
 Murray R 28(5) 123-5
 Murray RJ 28(6) 155
 Murtagh JE 29(4) 94-6
 Neal B 27(4) 98-101
 Neeskens P 30(2) 47-50
 Newell C 27(1) 19-21
 Newgreen DB 28(1) 18-9
 Ng CS 30(3) 67
 Ngeow WC 28(5) 113-5
 Nisselle P 27(5) 108-9
 O'Dempsey K 28(3) 55-8
 Ogle SJ 29(3) 58-9
 Olver I 29(4) 97-8
 Olver JS 30(4) 86-8
 Ooi C 30(1) 8-13
 Page MM 30(4) 98-101
 Pain MCF 29(3) 70
 Paine M 28(4) 94-7
 Palmer GM 27(4) 87
 Parker M 27(2) 28-33
 Pascoe G 28(1) 5-7
 Pashen D 27(1) 8
 Patounas MP 30(1) 14-16
 Paull J 27(2) 28-33
 Pavlakis N 29(6) 151-3
 Pearce G 30(4) 88-90
 Pearson K 28(4) 90
 Pelsler D 27(5) 109-13; 27(2)
 28-33
 Penny B 30(5) 130-3
 Peterson GM 29(5) 121; 28(4)
 84-7; 27(5) 109-13
 Pillans P 29(4) 99-101
 Post JJ 28(6) 146-9
 Proietto J 27(5) 118-9
 Pyle DI 30(3) 70-3
 Radford T 27(2) 28-33
 Rafter N 28(4) 82-3
 Rahman M 28(6) 136-9
 Ramzan I 30(2) 41-3; 29(2) 40-2
 Rane W 27(2) 28-33
 Reddel SW 30(6) 156-60
 Reeve J 28(1) 14-6; 27(5) 109-13
 Reeves G 30(3) 74-6
 Reid DB 27(2) 28-33
 Rey JM 28(5) 111-3
 Rice J 28(6) 136-9
 Riminton S 29(5) 130-3
 Roberts GW 27(3) 75-6
 Roberts S 28(6) 136-9
 Robertson J 27(6) 138-41
 Robinson A 27(1) 16-8
 Robinson J 29(3) 83
 Rodrigues G 29(3) 59-62
 Ruffin R 27(1) 13
 Ruse W 28(5) 113-5
 Sarre R 28(1) 16-7
 Schofield P 28(6) 134-5
 Schug SA 27(6) 152-4
 Scott I 31(1) 12-6
 Scott KF 27(1) 14-5
 Segelov E 29(1) 2-3
 Sharma R 29(1) 9-12
 Shenfield GM 28(3) 54-5
 Siderov J 30(1) 24-5; 28(5) 119
 Siebert D 30(2) 30-1
 Sinha Y 28(4) 84-7
 Skyring T 27(4) 82-3
 Smith AJ 30(3) 58-9; 28(2) 34-7
 Smith RL 29(1) 18-21
 Smith WB 31(1) 8-10
 Soh T 27(5) 113
 Somerville-Brown LM 30(4)
 98-101
 Somogyi A 29(6) 149-50; 28(3)
 55-8; 27(2) 47-9
 Steiner M 31(1) 16-17
 Stewart K 27(4) 80-1
 Stobie PJ 28(6) 136-9
 Stockigt JR 29(2) 32-5; 29(1)
 3-5; 27(2) 28-33
 Street A 27(4) 88-92
 Sturman N 27(6) 138-41
 Subbaraju P 27(6) 155
 Sullivan JR 28(3) 59-61
 Sved Williams A 30(5) 125-7
 Swaminathan S 29(5) 130-3
 Taverner D 29(5) 121
 Taylor RJ 28(4) 84-7
 Taylor T 29(6) 149-50
 Thomas B 29(5) 121
 Titchen T 27(3) 55-7
 Tompson A 29(5) 121
 Tong WWY 30(1) 25-6
 Tonkin AL 28(5) 110-1
 Toop L 29(2) 30-2
 Torpy DJ 30(6) 147-9
 Trabinger J 28(2) 29-33
 Tran HA 29(2) 48-52; 28(4)
 98-101; 28(2) 29-33
 Trevillian P 29(4) 102-8
 Turnbull F 27(4) 98-101
 Uahwatanasakul W 28(1) 2-5
 Van Gool K 30(3) 59-63
 Vardy J 31(1) 22-4
 Verras P 28(5) 126-9
 Vial J 27(5) 109-13
 Vitry A 28(2) 29-33; 27(1) 4-6
 Vivian D 30(3) 59-63
 Viviers L 27(6) 158
 Walker JB 30(4) 88-90
 Walsh JF 30(1) 3-4
 Walters S 30(2) 32-4
 Wark PAB 29(5) 118-9
 Watts RW 27(2) 34-5
 Weatherill C 29(4) 91-3
 Weerasuriya K 29(2) 32-5
 Welbourne D 27(6) 155
 Westbury J 31(1) 3-4
 Whitehouse M 28(1) 5-7
 Whitworth JA 27(6) 137-8
 Wilce H 27(3) 58-9
 Wilcox RA 29(1) 21

Wilkinson R 28(2) 41
Williams D 28(6) 143-5
Williams K 30(2) 32-4
Wilson I 27(2) 50
Wodak A 29(1) 8
Wolthers T 27(5) 109-13
Wong J 27(4) 93-6
Wong RCW 29(6) 162-4
Wood ML 29(1) 6-8
Woods RG 28(4) 101; 28(3)
54-5; 28(2) 41
Woodward A 28(4) 82-3
Worsnop C 28(2) 26-8
Worthley DL 28(3) 62-6
Wu J 30(4) 102-5
Yeung SPS 27(4) 87
Yue D 27(4) 93-6
Zaninovich L 30(5) 116
Zwar N 29(3) 80-2